{
  "meta": {
    "id": "test2",
    "title": "Anti-Cancer Drugs & Immunosuppressants",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "All the following statements are true regarding ifosfamide except?",
      "options": [
        {
          "label": "A",
          "text": "It is metabolized by cytochrome p450 enzymes",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is less neurotoxic than cyclophosphamide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Chloroacetaldehyde is the metabolite of ifosfamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is an alkylating agent",
          "correct": false
        }
      ],
      "correct_answer": "B. It is less neurotoxic than cyclophosphamide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Less neurotoxic than cyclophosphamide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is metabolized by cytochrome p450 enzymes: This statement is true. Ifosfamide , like many other alkylating agents including cyclophosphamide , is metabolized by cytochrome p450 enzymes, which play a key role in its activation and detoxification.</li><li>\u2022 Option A. It is metabolized by cytochrome p450 enzymes:</li><li>\u2022 true.</li><li>\u2022 Ifosfamide</li><li>\u2022 alkylating agents</li><li>\u2022 cyclophosphamide</li><li>\u2022 cytochrome p450 enzymes,</li><li>\u2022 activation and detoxification.</li><li>\u2022 Option C. Chloroacetaldehyde is the metabolite of ifosfamide: This is also true . The metabolism of ifosfamide involves the production of chloroacetaldehyde , a metabolite that contributes to its nephrotoxic effects.</li><li>\u2022 Option C. Chloroacetaldehyde is the metabolite of ifosfamide:</li><li>\u2022 true</li><li>\u2022 ifosfamide</li><li>\u2022 production of chloroacetaldehyde</li><li>\u2022 metabolite</li><li>\u2022 its nephrotoxic effects.</li><li>\u2022 Option D. It is an alkylating agent: This statement is correct . Ifosfamide belongs to the nitrogen mustard group of alkylating agents, which are used in cancer chemotherapy to alkylate the DNA of cancer cells , leading to cell death.</li><li>\u2022 Option D. It is an alkylating agent:</li><li>\u2022 correct</li><li>\u2022 Ifosfamide</li><li>\u2022 nitrogen mustard group of alkylating agents,</li><li>\u2022 cancer chemotherapy</li><li>\u2022 alkylate the DNA of cancer cells</li><li>\u2022 cell death.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ifosfamide, while being a valuable chemotherapeutic alkylating agent , carries a significant risk of neurotoxicity that is greater than that of cyclophosphamide. This fact must be carefully considered when prescribing and managing treatment with ifosfamide in clinical practice.</li><li>\u27a4 Ifosfamide,</li><li>\u27a4 chemotherapeutic alkylating agent</li><li>\u27a4 risk of neurotoxicity</li><li>\u27a4 greater than</li><li>\u27a4 cyclophosphamide.</li><li>\u27a4 carefully considered</li><li>\u27a4 prescribing and managing treatment with ifosfamide</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dd43d6cd",
      "audio": ""
    },
    {
      "text": "All the following statements about methotrexate are correct except:",
      "options": [
        {
          "label": "A",
          "text": "Folinic acid enhances the action of methotrexate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Methotrexate acts by inhibiting dihydrofolate reductase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non-proliferative cells are relatively resistant to methotrexate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Methotrexate can be used in the treatment of psoriasis",
          "correct": false
        }
      ],
      "correct_answer": "A. Folinic acid enhances the action of methotrexate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Folinic acid enhances the action of methotrexate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Methotrexate acts by inhibiting dihydrofolate reductase: This statement is correct . Methotrexate is an anti-metabolite that inhibits DHFRase, reducing the formation of tetrahydrofolate required for purine and thymidylate synthesis , which are essential for DNA replication and cell division.</li><li>\u2022 Option B. Methotrexate acts by inhibiting dihydrofolate reductase:</li><li>\u2022 correct</li><li>\u2022 anti-metabolite</li><li>\u2022 inhibits DHFRase, reducing</li><li>\u2022 tetrahydrofolate</li><li>\u2022 purine and thymidylate synthesis</li><li>\u2022 DNA replication and cell division.</li><li>\u2022 Option C. Non-proliferative cells are relatively resistant to methotrexate: This is correct. Methotrexate's mechanism targets the S-phase of the cell cycle, affecting rapidly dividing cells; thus, cells that are in a resting state show relative resistance.</li><li>\u2022 Option C. Non-proliferative cells are relatively resistant to methotrexate:</li><li>\u2022 correct.</li><li>\u2022 S-phase of the cell cycle,</li><li>\u2022 rapidly dividing cells;</li><li>\u2022 resting state show relative resistance.</li><li>\u2022 Option D. Methotrexate can be used in the treatment of psoriasis: This statement is true . Beyond its oncological applications, methotrexate is used as a first-line disease-modifying anti-rheumatic drug (DMARD) and is effective for conditions like psoriasis and ectopic pregnancy due to its anti-proliferative effects on fast-dividing cells.</li><li>\u2022 Option D. Methotrexate can be used in the treatment of psoriasis:</li><li>\u2022 true</li><li>\u2022 first-line disease-modifying anti-rheumatic drug (DMARD)</li><li>\u2022 effective</li><li>\u2022 psoriasis and</li><li>\u2022 ectopic pregnancy</li><li>\u2022 anti-proliferative effects</li><li>\u2022 fast-dividing cells.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Methotrexate is a critical drug used for a variety of conditions, including as the drug of choice for choriocarcinoma and a first-line DMARD . It is essential to understand that while methotrexate inhibits DHFRase, leading to decreased DNA synthesis in proliferating cells, folinic acid is used to rescue normal cells from its toxic effects, not enhance its action.</li><li>\u27a4 Methotrexate</li><li>\u27a4 critical drug</li><li>\u27a4 drug of choice for choriocarcinoma</li><li>\u27a4 first-line</li><li>\u27a4 DMARD</li><li>\u27a4 essential</li><li>\u27a4 methotrexate inhibits DHFRase,</li><li>\u27a4 decreased DNA synthesis</li><li>\u27a4 proliferating cells, folinic acid</li><li>\u27a4 rescue normal cells</li><li>\u27a4 toxic effects, not</li><li>\u27a4 action.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7ffb33e6",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman named Hema has locally advanced breast cancer and has been recommended for chemotherapy. She has a history of myocardial infarction and congestive heart failure. Which antineoplastic drug should be avoided in her treatment?",
      "options": [
        {
          "label": "A",
          "text": "Anthracyclines",
          "correct": true
        },
        {
          "label": "B",
          "text": "Alkylating agents",
          "correct": false
        },
        {
          "label": "C",
          "text": "Platinum compounds",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bisphosphonates",
          "correct": false
        }
      ],
      "correct_answer": "A. Anthracyclines",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Anthracyclines</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Alkylating agents: Incorrect because while alkylating agents are used in breast cancer treatment , they are not specifically associated with increased risk of cardiotoxicity, which is Hema's primary concern given her cardiac history.</li><li>\u2022 Option B. Alkylating agents:</li><li>\u2022 Incorrect</li><li>\u2022 alkylating agents</li><li>\u2022 breast cancer treatment</li><li>\u2022 not</li><li>\u2022 increased risk of cardiotoxicity,</li><li>\u2022 Hema's primary</li><li>\u2022 cardiac history.</li><li>\u2022 Option C. Platinum compounds: Incorrect as platinum compounds, commonly used in various cancers including breast cancer, do not have a direct link to cardiotoxicity that would particularly exacerbate Hema\u2019s existing heart conditions.</li><li>\u2022 Option C. Platinum compounds:</li><li>\u2022 Incorrect</li><li>\u2022 platinum compounds,</li><li>\u2022 various cancers</li><li>\u2022 breast cancer,</li><li>\u2022 not</li><li>\u2022 direct link to cardiotoxicity</li><li>\u2022 exacerbate Hema\u2019s existing heart conditions.</li><li>\u2022 Option D. Bisphosphonates: Incorrect because bisphosphonates are not primarily antineoplastic drugs but are used to manage bone metastases and prevent bone loss in cancer patients undergoing hormonal therapy. They do not pose a risk of cardiotoxicity, though they have other side effects like renal dysfunction and osteonecrosis of the jaw.</li><li>\u2022 Option D. Bisphosphonates:</li><li>\u2022 Incorrect</li><li>\u2022 bisphosphonates</li><li>\u2022 not</li><li>\u2022 antineoplastic drugs</li><li>\u2022 bone metastases</li><li>\u2022 prevent bone loss in cancer patients</li><li>\u2022 hormonal therapy.</li><li>\u2022 do not</li><li>\u2022 risk of cardiotoxicity,</li><li>\u2022 other side effects</li><li>\u2022 renal dysfunction and osteonecrosis of the jaw.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For a patient with a history of heart disease , it is crucial to avoid anthracyclines due to their potential to cause severe cardiotoxicity. Alternative chemotherapy agents should be considered that do not exacerbate heart conditions.</li><li>\u27a4 history of heart disease</li><li>\u27a4 avoid anthracyclines</li><li>\u27a4 cause severe cardiotoxicity.</li><li>\u27a4 Alternative chemotherapy</li><li>\u27a4 should be</li><li>\u27a4 do not exacerbate heart conditions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2692847d",
      "audio": ""
    },
    {
      "text": "All are true about Erlotinib except?",
      "options": [
        {
          "label": "A",
          "text": "Used in non-small cell carcinoma of lung",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Food decreases absorption",
          "correct": true
        },
        {
          "label": "D",
          "text": "It causes skin rashes and diarrhoea",
          "correct": false
        }
      ],
      "correct_answer": "C. Food decreases absorption",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Food decreases absorption</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Used in non-small cell carcinoma of lung: This statement is correct. Erlotinib is indeed used for treating non-small cell lung carcinoma , acting primarily by inhibiting the EGFR pathways involved in cancer cell proliferation.</li><li>\u2022 Option A. Used in non-small cell carcinoma of lung:</li><li>\u2022 correct.</li><li>\u2022 non-small cell lung carcinoma</li><li>\u2022 inhibiting the EGFR pathways</li><li>\u2022 cancer cell proliferation.</li><li>\u2022 Option B. It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist: This is also true . Erlotinib inhibits the activity of the EGFR , which is a tyrosine kinase, thereby interfering with the growth and survival of cancer cells.</li><li>\u2022 Option B. It is a small molecule tyrosine kinase inhibitor acting as EGFR antagonist:</li><li>\u2022 true</li><li>\u2022 inhibits</li><li>\u2022 activity of</li><li>\u2022 EGFR</li><li>\u2022 tyrosine kinase,</li><li>\u2022 growth and survival of cancer cells.</li><li>\u2022 Option D. It causes skin rashes and diarrhoea: Accurate as well. The most common adverse effects associated with Erlotinib include an acneiform skin rash and diarrhea , along with other side effects like anorexia and fatigue.</li><li>\u2022 Option D. It causes skin rashes and diarrhoea:</li><li>\u2022 common adverse effects</li><li>\u2022 Erlotinib</li><li>\u2022 acneiform skin rash and diarrhea</li><li>\u2022 other side effects</li><li>\u2022 anorexia and fatigue.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Erlotinib is a tyrosine kinase inhibitor used notably for non-small cell lung carcinoma and pancreatic carcinoma . Additionally, the absorption of Erlotinib is increased by food, which is an important consideration for its clinical use.</li><li>\u27a4 Erlotinib</li><li>\u27a4 tyrosine kinase inhibitor</li><li>\u27a4 non-small cell lung carcinoma and pancreatic carcinoma</li><li>\u27a4 absorption of Erlotinib</li><li>\u27a4 increased by food,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bbbbf455",
      "audio": ""
    },
    {
      "text": "A 65-year-old male presents with a cough, shortness of breath, and chest pain. Imaging studies reveal a mass in the lung, and a biopsy confirms the diagnosis of carcinoma lung. The patient has a history of chronic obstructive pulmonary disease (COPD) and bronchiectasis. He is currently on bronchodilators, inhaled corticosteroids, and oxygen therapy. The oncologist recommends chemotherapy for the treatment of the cancer. Which of the following drugs should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Vinblastine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bleomycin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Mithramycin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adriamycin",
          "correct": false
        }
      ],
      "correct_answer": "B. Bleomycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Bleomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Vinblastine: While Vinblastine can have its own set of side effect s, including bone marrow suppression and neurotoxicity , it does not specifically exacerbate lung conditions like COPD or bronchiectasis, making it a safer option than Bleomycin.</li><li>\u2022 Option A. Vinblastine:</li><li>\u2022 side effect</li><li>\u2022 bone marrow suppression</li><li>\u2022 neurotoxicity</li><li>\u2022 does not</li><li>\u2022 exacerbate lung</li><li>\u2022 conditions</li><li>\u2022 COPD or bronchiectasis,</li><li>\u2022 safer</li><li>\u2022 Option C. Mithramycin: This drug is used in the treatment of testicular cancer and certain types of hypercalcemia but is less commonly associated with pulmonary complications, making it a potentially safer option for this patient.</li><li>\u2022 Option C. Mithramycin:</li><li>\u2022 testicular cancer</li><li>\u2022 certain types</li><li>\u2022 hypercalcemia</li><li>\u2022 less</li><li>\u2022 pulmonary complications,</li><li>\u2022 safer option</li><li>\u2022 Option D. Adriamycin (Doxorubicin): Adriamycin is known for its cardiotoxicity rather than pulmonary toxicity, and therefore, it does not pose the same specific risk to patients with pre-existing lung diseases as Bleomycin .</li><li>\u2022 Option D. Adriamycin (Doxorubicin):</li><li>\u2022 cardiotoxicity rather than pulmonary toxicity,</li><li>\u2022 does not pose</li><li>\u2022 risk to patients with pre-existing lung diseases as Bleomycin</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with pre-existing lung conditions such as COPD and bronchiectasis, Bleomycin should be avoided due to its potential to cause significant pulmonary toxicity.</li><li>\u27a4 pre-existing lung</li><li>\u27a4 COPD and bronchiectasis, Bleomycin</li><li>\u27a4 avoided</li><li>\u27a4 potential to</li><li>\u27a4 pulmonary toxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb430962",
      "audio": ""
    },
    {
      "text": "The most common side effect of cancer chemotherapy is nausea with or without vomiting. The anticancer drugs vary is their ability to cause nausea and vomiting. Which of the following anti-cancer drugs is least likely to cause nausea and vomiting?",
      "options": [
        {
          "label": "A",
          "text": "Chlorambucil",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cisplatin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Doxorubicin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Daunorubicin",
          "correct": false
        }
      ],
      "correct_answer": "A. Chlorambucil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Chlorambucil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Cisplatin: Known for its high emetogenic potential, cisplatin is a platinum-based drug that often requires premedication with antiemetics to manage its severe nausea and vomiting side effects.</li><li>\u2022 Option B. Cisplatin:</li><li>\u2022 high emetogenic potential,</li><li>\u2022 platinum-based drug</li><li>\u2022 premedication</li><li>\u2022 with antiemetics</li><li>\u2022 severe nausea and vomiting</li><li>\u2022 Option C. Doxorubicin: As an anthracycline, doxorubicin has a moderate to high emetogenic potential , necessitating the use of antiemetics for patient comfort during treatment.</li><li>\u2022 Option C. Doxorubicin:</li><li>\u2022 anthracycline, doxorubicin</li><li>\u2022 moderate to high emetogenic potential</li><li>\u2022 use of</li><li>\u2022 antiemetics</li><li>\u2022 comfort during treatment.</li><li>\u2022 Option D. Daunorubicin: Similar in class to doxorubicin , daunorubicin also has a moderate to high emetogenic risk, which can affect patient quality of life and treatment adherence.</li><li>\u2022 Option D. Daunorubicin:</li><li>\u2022 Similar</li><li>\u2022 doxorubicin</li><li>\u2022 daunorubicin</li><li>\u2022 moderate to high emetogenic risk,</li><li>\u2022 quality of life and treatment adherence.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When considering the side effect profile of chemotherapeutic agents, especially regarding emesis, chlorambucil is noted for its lower likelihood of causing nausea and vomiting relative to other agents like cisplatin, doxorubicin, and daunorubicin.</li><li>\u27a4 side effect</li><li>\u27a4 chemotherapeutic agents,</li><li>\u27a4 emesis,</li><li>\u27a4 chlorambucil</li><li>\u27a4 lower likelihood</li><li>\u27a4 nausea and vomiting</li><li>\u27a4 cisplatin, doxorubicin, and daunorubicin.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cc2bc55b",
      "audio": ""
    },
    {
      "text": "Which of the following medications is essential for ameliorating the toxicity of pemetrexed?",
      "options": [
        {
          "label": "A",
          "text": "Folinic acid and vitamin B6",
          "correct": false
        },
        {
          "label": "B",
          "text": "Folic acid and vitamin B12",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vitamin B6 and vitamin B12",
          "correct": false
        },
        {
          "label": "D",
          "text": "Folic acid and dexamethasone",
          "correct": false
        }
      ],
      "correct_answer": "B. Folic acid and vitamin B12",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Folic acid and vitamin B12</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Folinic acid and vitamin B6: This combination is incorrect as folinic acid, while related to folate, is not used to mitigate the toxicity associated with pemetrexed, and vitamin B6 does not play a role in mitigating pemetrexed's specific toxic effects .</li><li>\u2022 Option A. Folinic acid and vitamin B6:</li><li>\u2022 incorrect as folinic acid,</li><li>\u2022 not</li><li>\u2022 vitamin B6 does not</li><li>\u2022 mitigating pemetrexed's specific toxic effects</li><li>\u2022 Option C. Vitamin B6 and vitamin B12: Vitamin B12 is correct in part; however, vitamin B6 does not aid in ameliorating the specific toxicities of pemetrexed.</li><li>\u2022 Option C. Vitamin B6 and vitamin B12:</li><li>\u2022 correct</li><li>\u2022 vitamin B6</li><li>\u2022 does not</li><li>\u2022 ameliorating</li><li>\u2022 specific</li><li>\u2022 toxicities of pemetrexed.</li><li>\u2022 Option D. Folic acid and dexamethasone: While folic acid is a correct component , dexamethasone is primarily used for its anti-inflammatory properties and not for mitigating myelosuppression caused by pemetrexed.</li><li>\u2022 Option D. Folic acid and dexamethasone:</li><li>\u2022 folic acid</li><li>\u2022 correct component</li><li>\u2022 dexamethasone</li><li>\u2022 anti-inflammatory properties</li><li>\u2022 not for</li><li>\u2022 mitigating myelosuppression</li><li>\u2022 pemetrexed.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For patients undergoing treatment with pemetrexed , it is crucial to supplement with folic acid and vitamin B12 to reduce the risk of myelosuppression and related complications. This supplementation strategy helps maintain necessary folate and vitamin B12 levels , supporting DNA synthesis and red blood cell maturation , thereby counteracting the drug's potential hematological toxicities.</li><li>\u27a4 patients</li><li>\u27a4 treatment with pemetrexed</li><li>\u27a4 crucial to supplement</li><li>\u27a4 folic acid and vitamin B12</li><li>\u27a4 reduce the risk of</li><li>\u27a4 myelosuppression</li><li>\u27a4 complications.</li><li>\u27a4 maintain necessary folate and vitamin B12</li><li>\u27a4 levels</li><li>\u27a4 supporting DNA synthesis and red blood cell maturation</li><li>\u27a4 counteracting the drug's</li><li>\u27a4 hematological toxicities.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ab0f6a9e",
      "audio": ""
    },
    {
      "text": "Which of the following statements about rituximab is false?",
      "options": [
        {
          "label": "A",
          "text": "It is a chimeric monoclonal antibody against CD-20",
          "correct": false
        },
        {
          "label": "B",
          "text": "It has dose dependent kinetics",
          "correct": true
        },
        {
          "label": "C",
          "text": "It is used for treatment of non- Hodgkin lymphoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Its most common adverse effect is infusion related reactions",
          "correct": false
        }
      ],
      "correct_answer": "B. It has dose dependent kinetics",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It has dose dependent kinetics.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is a chimeric monoclonal antibody against CD-20: This statement is true and accurately describes the biological target of rituximab, essential for its efficacy in treating diseases like lymphomas where CD-20 positive B-cells are pathologically active.</li><li>\u2022 Option A. It is a chimeric monoclonal antibody against CD-20:</li><li>\u2022 true</li><li>\u2022 biological target</li><li>\u2022 rituximab,</li><li>\u2022 its efficacy in treating diseases</li><li>\u2022 lymphomas</li><li>\u2022 CD-20 positive B-cells are pathologically active.</li><li>\u2022 Option C. It is used for treatment of non-Hodgkin lymphoma: True. Rituximab is extensively used in the treatment of non-Hodgkin lymphoma among other lymphoid malignancies, leveraging its ability to target CD-20 for therapeutic effect.</li><li>\u2022 Option C. It is used for treatment of non-Hodgkin lymphoma:</li><li>\u2022 True. Rituximab</li><li>\u2022 used in</li><li>\u2022 non-Hodgkin</li><li>\u2022 lymphoma</li><li>\u2022 lymphoid malignancies,</li><li>\u2022 CD-20</li><li>\u2022 therapeutic effect.</li><li>\u2022 Option D. Its most common adverse effect is infusion related reactions: Also true . Infusion-related reactions occur in about half of all patients during the first infusion of rituximab, though the risk decreases with subsequent treatments. Pre-medicating with steroids or antihistamines can mitigate these reactions.</li><li>\u2022 Option D. Its most common adverse effect is infusion related reactions:</li><li>\u2022 true</li><li>\u2022 Infusion-related reactions</li><li>\u2022 half of</li><li>\u2022 all patients</li><li>\u2022 first infusion of rituximab,</li><li>\u2022 risk decreases</li><li>\u2022 subsequent treatments.</li><li>\u2022 Pre-medicating</li><li>\u2022 steroids or antihistamines</li><li>\u2022 mitigate</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Rituximab, a chimeric monoclonal antibody targeting CD-20 B-cells, is primarily used to treat various hematological malignancies and some autoimmune conditions . Its pharmacokinetics does not follow dose-dependent kinetics but instead exhibits first-order kinetics, meaning its clearance remains constant across different plasma concentrations.</li><li>\u27a4 Rituximab,</li><li>\u27a4 chimeric monoclonal antibody</li><li>\u27a4 primarily used</li><li>\u27a4 hematological malignancies</li><li>\u27a4 autoimmune conditions</li><li>\u27a4 pharmacokinetics does not</li><li>\u27a4 dose-dependent kinetics</li><li>\u27a4 exhibits first-order</li><li>\u27a4 kinetics,</li><li>\u27a4 clearance remains constant</li><li>\u27a4 different plasma concentrations.</li><li>\u27a4 In contrast, dose-dependent kinetics (zero-order kinetics) describes a scenario where the drug\u2019s clearance rate and half-life change with varying doses , which is not the case with rituximab . This differentiates rituximab from drugs like warfarin and phenytoin , which follow zero-order kinetics at therapeutic or higher doses.</li><li>\u27a4 contrast,</li><li>\u27a4 dose-dependent kinetics (zero-order kinetics)</li><li>\u27a4 drug\u2019s clearance rate and half-life</li><li>\u27a4 varying doses</li><li>\u27a4 not</li><li>\u27a4 rituximab</li><li>\u27a4 differentiates rituximab</li><li>\u27a4 warfarin and phenytoin</li><li>\u27a4 zero-order kinetics</li><li>\u27a4 therapeutic or higher doses.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cc6de174",
      "audio": ""
    },
    {
      "text": "Thalidomide was once used for treating the emesis of pregnancy. Later, it was withdrawn from the market due to its side effects. However, it was reintroduced for certain indications like multiple myelomA. Which of the following is not a side effect of thalidomide?",
      "options": [
        {
          "label": "A",
          "text": "Peripheral neuropathy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diarrhea",
          "correct": true
        },
        {
          "label": "C",
          "text": "Teratogenicity",
          "correct": false
        },
        {
          "label": "D",
          "text": "Deep vein thrombosis",
          "correct": false
        }
      ],
      "correct_answer": "B. Diarrhea",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Diarrhea</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Peripheral neuropathy: Accurately listed as a side effect , it involves nerve damage resulting in pain, numbness, or tingling sensations, primarily in the hands and feet.</li><li>\u2022 Option A. Peripheral neuropathy:</li><li>\u2022 side effect</li><li>\u2022 nerve damage</li><li>\u2022 pain, numbness, or tingling</li><li>\u2022 sensations,</li><li>\u2022 hands and feet.</li><li>\u2022 Option C. Teratogenicity: Correctly identified as a side effect , thalidomide causes severe birth defects, a major reason for its initial market withdrawal.</li><li>\u2022 Option C. Teratogenicity:</li><li>\u2022 Correctly</li><li>\u2022 side effect</li><li>\u2022 thalidomide</li><li>\u2022 severe birth defects,</li><li>\u2022 initial</li><li>\u2022 market withdrawal.</li><li>\u2022 Option D. Deep vein thrombosis: This is a valid side effect , with thalidomide increasing the risk for blood clots, necessitating caution and preventive measures in its administration.</li><li>\u2022 Option D. Deep vein thrombosis:</li><li>\u2022 valid side effect</li><li>\u2022 increasing the risk for blood clots,</li><li>\u2022 caution and preventive</li><li>\u2022 its administration.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Major adverse effects of thalidomide:</li><li>\u27a4 Major adverse effects of thalidomide:</li><li>\u27a4 Teratogenicity: Thalidomide is associated with severe birth defects , particularly limb abnormalities, when taken during pregnancy. Peripheral neuropathy : Thalidomide can cause nerve damage that results in tingling, numbness, or pain in the hands and feet. Thromboembolism : Thalidomide use is associated with an increased risk of blood clots, including deep vein thrombosis and pulmonary embolism. Somnolence : Thalidomide can cause drowsiness or sedation , which may impair the ability to perform tasks that require alertness. Bradycardia: Thalidomide may cause a slow heart rate , which can lead to dizziness or fainting. Constipation : Thalidomide can cause gastrointestinal symptoms such as constipation, nausea, and vomiting. Hypersensitivity reactions : Thalidomide can cause allergic reactions , including rash, itching, and difficulty breathing.</li><li>\u27a4 Teratogenicity: Thalidomide is associated with severe birth defects , particularly limb abnormalities, when taken during pregnancy.</li><li>\u27a4 Teratogenicity:</li><li>\u27a4 Thalidomide</li><li>\u27a4 severe birth defects</li><li>\u27a4 limb abnormalities,</li><li>\u27a4 during</li><li>\u27a4 pregnancy.</li><li>\u27a4 Peripheral neuropathy : Thalidomide can cause nerve damage that results in tingling, numbness, or pain in the hands and feet.</li><li>\u27a4 Peripheral neuropathy</li><li>\u27a4 nerve damage</li><li>\u27a4 tingling, numbness, or pain</li><li>\u27a4 hands</li><li>\u27a4 and feet.</li><li>\u27a4 Thromboembolism : Thalidomide use is associated with an increased risk of blood clots, including deep vein thrombosis and pulmonary embolism.</li><li>\u27a4 Thromboembolism</li><li>\u27a4 increased risk of blood clots,</li><li>\u27a4 deep vein thrombosis</li><li>\u27a4 pulmonary embolism.</li><li>\u27a4 Somnolence : Thalidomide can cause drowsiness or sedation , which may impair the ability to perform tasks that require alertness.</li><li>\u27a4 Somnolence</li><li>\u27a4 drowsiness or sedation</li><li>\u27a4 impair the ability</li><li>\u27a4 perform tasks</li><li>\u27a4 alertness.</li><li>\u27a4 Bradycardia: Thalidomide may cause a slow heart rate , which can lead to dizziness or fainting.</li><li>\u27a4 Bradycardia:</li><li>\u27a4 cause a slow heart rate</li><li>\u27a4 dizziness or fainting.</li><li>\u27a4 Constipation : Thalidomide can cause gastrointestinal symptoms such as constipation, nausea, and vomiting.</li><li>\u27a4 Constipation</li><li>\u27a4 gastrointestinal symptoms such as constipation, nausea, and vomiting.</li><li>\u27a4 Hypersensitivity reactions : Thalidomide can cause allergic reactions , including rash, itching, and difficulty breathing.</li><li>\u27a4 Hypersensitivity reactions</li><li>\u27a4 allergic reactions</li><li>\u27a4 rash, itching, and difficulty breathing.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "307c16eb",
      "audio": ""
    },
    {
      "text": "A 56-year-old female presents with breast carcinoma, and she was prescribed Herceptin (trastuzumab). Which of the following statements regarding this drug is true?",
      "options": [
        {
          "label": "A",
          "text": "It is an antibody produced entirely from mice containing no human component",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is a monoclonal antibody produced by injecting the HER2 antigen",
          "correct": true
        },
        {
          "label": "C",
          "text": "It is a polyclonal antibody",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is a monoclonal antibody containing only human components",
          "correct": false
        }
      ],
      "correct_answer": "B. It is a monoclonal antibody produced by injecting the HER2 antigen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It is a monoclonal antibody produced by injecting the HER2 antigen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is an antibody produced entirely from mice containing no human component: This statement is incorrect. Trastuzumab is not a fully murine ( mouse-derived ) antibody. It is, in fact, a humanized monoclonal antibody, which means it is predominantly of human origin , but with mouse-derived antigen-binding regions.</li><li>\u2022 Option A.</li><li>\u2022 It is an antibody produced entirely from mice containing no human component:</li><li>\u2022 incorrect.</li><li>\u2022 Trastuzumab</li><li>\u2022 not</li><li>\u2022 fully murine</li><li>\u2022 mouse-derived</li><li>\u2022 antibody.</li><li>\u2022 humanized monoclonal antibody,</li><li>\u2022 predominantly of</li><li>\u2022 human origin</li><li>\u2022 mouse-derived antigen-binding regions.</li><li>\u2022 Option C. It is a polyclonal antibody: This statement is incorrect. Trastuzumab is a monoclonal antibody, meaning it is made by identical immune cells that are all clones of a unique parent cell , and it targets a specific epitope on the HER2 receptor.</li><li>\u2022 Option C. It is a polyclonal antibody:</li><li>\u2022 incorrect. Trastuzumab</li><li>\u2022 monoclonal antibody,</li><li>\u2022 identical immune cells</li><li>\u2022 clones</li><li>\u2022 unique parent cell</li><li>\u2022 targets a specific epitope</li><li>\u2022 HER2 receptor.</li><li>\u2022 Option D. It is a monoclonal antibody containing only human components: This is not accurate . Trastuzumab is humanized, meaning it combines both human and mouse antibody components. The majority of the antibody is human, with mouse components in the antigen-binding region.</li><li>\u2022 Option D.</li><li>\u2022 It is a monoclonal antibody containing only human components:</li><li>\u2022 not accurate</li><li>\u2022 Trastuzumab</li><li>\u2022 humanized,</li><li>\u2022 combines both human and mouse antibody components.</li><li>\u2022 majority</li><li>\u2022 antibody is human,</li><li>\u2022 mouse</li><li>\u2022 components</li><li>\u2022 antigen-binding region.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Trastuzumab (Herceptin) is a humanized monoclonal antibody used in the treatment of HER2-positive breast cancer. It is crucial to understand that it targets the HER2 receptor, which is overexpressed in certain aggressive forms of breast cancer , helping to inhibit the growth and spread of cancer cells.</li><li>\u27a4 Trastuzumab (Herceptin)</li><li>\u27a4 humanized monoclonal antibody</li><li>\u27a4 HER2-positive breast cancer.</li><li>\u27a4 targets the HER2 receptor,</li><li>\u27a4 overexpressed</li><li>\u27a4 aggressive forms of breast cancer</li><li>\u27a4 inhibit</li><li>\u27a4 growth and</li><li>\u27a4 spread of cancer cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "604fc2ba",
      "audio": ""
    },
    {
      "text": "Which of the following drugs acts specifically on the M phase of the cell cycle?",
      "options": [
        {
          "label": "A",
          "text": "Mitoxantrone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Topotecan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paclitaxel",
          "correct": true
        },
        {
          "label": "D",
          "text": "Daunorubicin",
          "correct": false
        }
      ],
      "correct_answer": "C. Paclitaxel",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-121414.png"
      ],
      "explanation": "<p><strong>Ans. C) Paclitaxel</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mitoxantrone: This drug is a type of antitumor antibiotic that interferes with DNA replication and RNA synthesis but does not specifically act on the M phase . It is classified among topoisomerase inhibitors and is used primarily for its action in various phases of the cell cycle, but not specifically the M phase.</li><li>\u2022 Option A. Mitoxantrone:</li><li>\u2022 type of antitumor antibiotic</li><li>\u2022 DNA replication and RNA synthesis</li><li>\u2022 does</li><li>\u2022 not</li><li>\u2022 M phase</li><li>\u2022 topoisomerase inhibitors</li><li>\u2022 its action</li><li>\u2022 phases of the cell cycle,</li><li>\u2022 not</li><li>\u2022 M phase.</li><li>\u2022 Option B. Topotecan: As a topoisomerase inhibitor, Topotecan interferes with the ability of topoisomerases to relieve torsional strain on DNA during replication and transcription . It is primarily active in the S phase of the cell cycle , not the M phase.</li><li>\u2022 Option B. Topotecan:</li><li>\u2022 topoisomerase inhibitor,</li><li>\u2022 interferes</li><li>\u2022 ability of topoisomerases</li><li>\u2022 relieve torsional</li><li>\u2022 strain on DNA during replication</li><li>\u2022 transcription</li><li>\u2022 primarily active</li><li>\u2022 S phase of the cell cycle</li><li>\u2022 Option D. Daunorubicin: Another antitumor antibiotic, Daunorubicin is involved in intercalating DNA and inhibiting the enzyme topoisomerase II, which prevents the relaxation of supercoiled DNA and promotes DNA breakage during replication . Like Mitoxantrone , it does not specifically target the M phase.</li><li>\u2022 Option D. Daunorubicin:</li><li>\u2022 Daunorubicin</li><li>\u2022 intercalating DNA</li><li>\u2022 inhibiting the enzyme</li><li>\u2022 topoisomerase II,</li><li>\u2022 prevents the relaxation of supercoiled DNA and promotes DNA breakage</li><li>\u2022 replication</li><li>\u2022 Mitoxantrone</li><li>\u2022 does not</li><li>\u2022 target the M phase.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "16fd3266",
      "audio": ""
    },
    {
      "text": "A 7-year-old child is started on chemotherapy. One of the medications used in the treatment is L-asparaginase. This drug works by depleting asparagine, an amino acid that is required for the growth and survival of leukemia cells. Which of the following cancers is L-asparaginase commonly used to treat?",
      "options": [
        {
          "label": "A",
          "text": "Acute lymphoblastic leukemia (ALL)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Acute Myeloblastic Leukemia (AML)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chronic lymphocyctic leukemia (CLL)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Chronic Myelocytic Leukemia (CML)",
          "correct": false
        }
      ],
      "correct_answer": "A. Acute lymphoblastic leukemia (ALL)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Acute lymphoblastic leukemia (ALL)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Acute Myeloblastic Leukemia (AML): AML is another type of leukemia but primarily affects different lineages of cells within the bone marrow . L-asparaginase is not typically used in the treatment of AML.</li><li>\u2022 Option B. Acute Myeloblastic Leukemia (AML):</li><li>\u2022 type of leukemia</li><li>\u2022 different lineages of cells</li><li>\u2022 bone marrow</li><li>\u2022 L-asparaginase</li><li>\u2022 not</li><li>\u2022 used</li><li>\u2022 AML.</li><li>\u2022 Option C. Chronic lymphocytic leukemia (CLL): CLL progresses more slowly than ALL and generally affects older adults. It is not treated with L-asparaginase.</li><li>\u2022 Option C. Chronic lymphocytic leukemia (CLL):</li><li>\u2022 progresses</li><li>\u2022 more slowly than ALL</li><li>\u2022 older adults.</li><li>\u2022 not</li><li>\u2022 L-asparaginase.</li><li>\u2022 Option D. Chronic Myelocytic Leukemia (CML): CML is a chronic form of leukemia affecting primarily adults . L-asparaginase is not effective against CML cells as they do not rely on external sources of asparagine like ALL cells.</li><li>\u2022 Option D. Chronic Myelocytic Leukemia (CML):</li><li>\u2022 chronic form of leukemia</li><li>\u2022 adults</li><li>\u2022 L-asparaginase</li><li>\u2022 not</li><li>\u2022 against CML cells</li><li>\u2022 do not</li><li>\u2022 external sources of asparagine</li><li>\u2022 ALL cells.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 L-asparaginase is particularly significant in the treatment of acute lymphoblastic leukemia (ALL) due to its unique mechanism of depleting asparagine , which is essential for the survival of ALL cells . This makes it a key component of chemotherapy regimens for ALL, especially in pediatric patients , where it can be combined with other drugs to enhance treatment efficacy and manage the disease effectively.</li><li>\u27a4 L-asparaginase</li><li>\u27a4 treatment of acute lymphoblastic leukemia (ALL)</li><li>\u27a4 depleting asparagine</li><li>\u27a4 essential for the survival of ALL cells</li><li>\u27a4 key component</li><li>\u27a4 chemotherapy regimens</li><li>\u27a4 ALL,</li><li>\u27a4 pediatric patients</li><li>\u27a4 combined with other drugs</li><li>\u27a4 treatment efficacy and</li><li>\u27a4 disease effectively.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a48d2ebc",
      "audio": ""
    },
    {
      "text": "Which of the following is false about tofacitinib and tocilizumab?",
      "options": [
        {
          "label": "A",
          "text": "Tofacitinib inhibits Janus kinase (JAK) enzymes",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tocilizumab is approved for the treatment of rheumatoid arthritis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tofacitinib is administered by intravenous route",
          "correct": true
        }
      ],
      "correct_answer": "D. Tofacitinib is administered by intravenous route",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-122248.png"
      ],
      "explanation": "<p><strong>Ans. D) Tofacitinib is administered by intravenous route</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tofacitinib inhibits Janus kinase (JAK) enzymes. True. Tofacitinib functions as a Janus kinase inhibitor, targeting and inhibiting these enzymes , which are crucial in the signaling pathways for various inflammatory processes.</li><li>\u2022 Option A. Tofacitinib inhibits Janus kinase (JAK) enzymes.</li><li>\u2022 True.</li><li>\u2022 Tofacitinib functions</li><li>\u2022 Janus kinase inhibitor,</li><li>\u2022 targeting</li><li>\u2022 inhibiting these enzymes</li><li>\u2022 crucial in the signaling pathways</li><li>\u2022 inflammatory processes.</li><li>\u2022 Option B. Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor - True. Tocilizumab is a monoclonal antibody that specifically binds to and inhibits the IL-6 receptor, thereby impacting the action of interleukin-6, a cytokine involved in inflammation.</li><li>\u2022 Option B. Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor -</li><li>\u2022 True.</li><li>\u2022 Tocilizumab</li><li>\u2022 monoclonal antibody</li><li>\u2022 specifically binds</li><li>\u2022 inhibits the IL-6 receptor,</li><li>\u2022 action of interleukin-6,</li><li>\u2022 cytokine</li><li>\u2022 inflammation.</li><li>\u2022 Option C. Tocilizumab is approved for the treatment of rheumatoid arthritis - True. Tocilizumab has been approved for the treatment of rheumatoid arthritis , particularly for patients who have not responded adequately to other treatments.</li><li>\u2022 Option C. Tocilizumab is approved for the treatment of rheumatoid arthritis -</li><li>\u2022 True. Tocilizumab</li><li>\u2022 approved for</li><li>\u2022 rheumatoid arthritis</li><li>\u2022 have not</li><li>\u2022 adequately to other treatments.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "09e91878",
      "audio": ""
    },
    {
      "text": "A 60-year-old patient with non-Hodgkin's lymphoma is undergoing chemotherapy. The oncologist discusses the mechanism of action of various chemotherapeutic agents to optimize the patient's treatment regimen. Understanding the specific phases of the cell cycle that these drugs target is crucial for effective therapy. Which of the following chemotherapeutic agents acts predominantly during the S phase of the cell cycle?",
      "options": [
        {
          "label": "A",
          "text": "Chlorambucil",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methotrexate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vincristine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paclitaxel",
          "correct": false
        }
      ],
      "correct_answer": "B. Methotrexate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Methotrexate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chlorambucil : This is an alkylating agent that acts primarily in the G1 and S phases, but it's not as specific to the S phase compared to some other drugs.</li><li>\u2022 Option A.</li><li>\u2022 Chlorambucil</li><li>\u2022 alkylating agent</li><li>\u2022 acts</li><li>\u2022 G1 and S phases,</li><li>\u2022 not as specific</li><li>\u2022 S phase</li><li>\u2022 some other drugs.</li><li>\u2022 Option C. Vincristine : Vincristine is a mitotic inhibitor that primarily acts on the M phase of the cell cycle . It inhibits microtubule formation, which is crucial for cell division.</li><li>\u2022 Option C.</li><li>\u2022 Vincristine</li><li>\u2022 mitotic inhibitor</li><li>\u2022 acts</li><li>\u2022 M phase of the cell cycle</li><li>\u2022 inhibits microtubule</li><li>\u2022 formation,</li><li>\u2022 crucial for cell division.</li><li>\u2022 Option D. Paclitaxel : Paclitaxel is also a mitotic inhibitor that acts mainly on the M phase. It stabilizes microtubules, preventing their disassembly, which is necessary for cell division.</li><li>\u2022 Option D.</li><li>\u2022 Paclitaxel</li><li>\u2022 mitotic inhibitor</li><li>\u2022 acts</li><li>\u2022 M phase.</li><li>\u2022 stabilizes microtubules,</li><li>\u2022 preventing</li><li>\u2022 disassembly,</li><li>\u2022 cell division.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Methotrexate's specific action of inhibiting DNA synthesis during the S phase.</li><li>\u27a4 Methotrexate's</li><li>\u27a4 inhibiting DNA synthesis</li><li>\u27a4 S phase.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "02aa8e30",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with breast cancer is undergoing chemotherapy. She is currently receiving a drug that acts on the 'S' phase of the cell cycle. Which of the following drugs is most likely being used in her treatment?",
      "options": [
        {
          "label": "A",
          "text": "Chlorambucil",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methotrexate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vincristine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paclitaxel",
          "correct": false
        }
      ],
      "correct_answer": "B. Methotrexate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Methotrexate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chlorambucil: This drug is an alkylating agent that is not specific to any particular phase of the cell cycle . It can form cross-links in DNA at any phase , thereby causing damage that leads to cell death. While effective against various cancers, it does not specifically target the S phase.</li><li>\u2022 Option A. Chlorambucil:</li><li>\u2022 alkylating agent</li><li>\u2022 not</li><li>\u2022 particular phase of the cell cycle</li><li>\u2022 cross-links in DNA</li><li>\u2022 at any phase</li><li>\u2022 damage</li><li>\u2022 cell death.</li><li>\u2022 against various cancers,</li><li>\u2022 does</li><li>\u2022 not</li><li>\u2022 S phase.</li><li>\u2022 Option C. Vincristine: Vincristine is a vinca alkaloid that acts predominantly during the M phase of the cell cycle. It inhibits microtubule formation , which is essential for mitotic spindle assembly and chromosome separation during mitosis.</li><li>\u2022 Option C. Vincristine:</li><li>\u2022 vinca alkaloid</li><li>\u2022 M phase of the cell cycle.</li><li>\u2022 inhibits</li><li>\u2022 microtubule formation</li><li>\u2022 mitotic spindle</li><li>\u2022 chromosome</li><li>\u2022 mitosis.</li><li>\u2022 Option D. Paclitaxel: Also acting in the M phase, Paclitaxel stabilizes microtubules and prevents their disassembly, thus inhibiting the completion of mitosis and leading to cell death.</li><li>\u2022 Option D. Paclitaxel:</li><li>\u2022 M phase,</li><li>\u2022 microtubules</li><li>\u2022 prevents</li><li>\u2022 disassembly,</li><li>\u2022 inhibiting</li><li>\u2022 completion of mitosis</li><li>\u2022 leading to cell death.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Methotrexate is a cell cycle-specific anticancer drug that acts by inhibiting DNA synthesis in the 'S' phase of the cell cycle. Chlorambucil is a cell cycle-nonspecific alkylating agent that can affect cells in any phase of the cell cycle. Vincristine and Paclitaxel are cell cycle-specific anticancer drug that acts in the 'M' phase of the cell cycle.</li><li>\u27a4 Methotrexate is a cell cycle-specific anticancer drug that acts by inhibiting DNA synthesis in the 'S' phase of the cell cycle.</li><li>\u27a4 Methotrexate</li><li>\u27a4 cell cycle-specific anticancer drug</li><li>\u27a4 inhibiting DNA synthesis</li><li>\u27a4 'S' phase</li><li>\u27a4 Chlorambucil is a cell cycle-nonspecific alkylating agent that can affect cells in any phase of the cell cycle.</li><li>\u27a4 Chlorambucil</li><li>\u27a4 cell cycle-nonspecific alkylating agent</li><li>\u27a4 any phase of the cell cycle.</li><li>\u27a4 Vincristine and Paclitaxel are cell cycle-specific anticancer drug that acts in the 'M' phase of the cell cycle.</li><li>\u27a4 Vincristine and Paclitaxel</li><li>\u27a4 cell cycle-specific anticancer drug</li><li>\u27a4 'M' phase of the cell cycle.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6a5fb933",
      "audio": ""
    },
    {
      "text": "A 52-year-old male with a history of chronic lymphocytic leukemia (CLL) is seen in the oncology clinic for a routine follow-up. His treatment regimen includes a purine analog, and his latest lab tests show a good response to the therapy. Which of the following statements is NOT true about purine analogs?",
      "options": [
        {
          "label": "A",
          "text": "Azathioprine is used as immunosuppressant drug",
          "correct": false
        },
        {
          "label": "B",
          "text": "Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fludarabine is the drug of choice for CLL.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cladribine is degraded by adenosine deaminase",
          "correct": true
        }
      ],
      "correct_answer": "D. Cladribine is degraded by adenosine deaminase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Cladribine is degraded by adenosine deaminase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Azathioprine is used as an immunosuppressant drug: True. Azathioprine inhibits DNA synthesis , effectively suppressing the immune response , which i s beneficial in conditions like autoimmune diseases and in preventing organ transplant rejection.</li><li>\u2022 Option A. Azathioprine is used as an immunosuppressant drug:</li><li>\u2022 True.</li><li>\u2022 inhibits DNA synthesis</li><li>\u2022 suppressing</li><li>\u2022 immune response</li><li>\u2022 s beneficial</li><li>\u2022 autoimmune diseases</li><li>\u2022 preventing organ transplant rejection.</li><li>\u2022 Option B. Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase): True. Drugs like mercaptopurine and thioguanine need activation by HGPRTase to exert their cytotoxic effects, making them effective in certain types of leukemia where this enzyme is active.</li><li>\u2022 Option B. Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase):</li><li>\u2022 True.</li><li>\u2022 mercaptopurine and thioguanine</li><li>\u2022 HGPRTase</li><li>\u2022 cytotoxic effects,</li><li>\u2022 effective</li><li>\u2022 types of leukemia</li><li>\u2022 enzyme is active.</li><li>\u2022 Option C. Fludarabine is the drug of choice for CLL: True. Fludarabine is commonly used and highly effective in the treatment of CLL due to its potent ability to interfere with DNA replication in the rapidly dividing leukemic cells.</li><li>\u2022 Option C. Fludarabine is the drug of choice for CLL:</li><li>\u2022 True.</li><li>\u2022 Fludarabine</li><li>\u2022 used and highly effective</li><li>\u2022 CLL</li><li>\u2022 potent ability</li><li>\u2022 interfere with DNA replication</li><li>\u2022 rapidly dividing leukemic cells.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Cladribine's resistance to adenosine deaminase makes it a particularly potent choice in certain leukemias , contrary to the incorrect claim of its degradation by this enzyme.</li><li>\u2022 Cladribine's resistance</li><li>\u2022 adenosine deaminase</li><li>\u2022 potent choice in certain leukemias</li><li>\u2022 incorrect</li><li>\u2022 its degradation by this enzyme.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3bd5f72",
      "audio": ""
    },
    {
      "text": "Which of the following statements best describes the mechanism of action of basiliximab?",
      "options": [
        {
          "label": "A",
          "text": "Basiliximab directly inhibits the proliferation of T-cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "Basiliximab promotes the activation of B-cells",
          "correct": false
        },
        {
          "label": "C",
          "text": "Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells",
          "correct": true
        },
        {
          "label": "D",
          "text": "Basiliximab enhances the differentiation of dendritic cells",
          "correct": false
        }
      ],
      "correct_answer": "C. Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Basiliximab directly inhibits the proliferation of T-cells: Incorrect. because basiliximab itself does not directly inhibit cell proliferation; instead, it prevents IL-2 from activating T-cells, which indirectly inhibits their proliferation.</li><li>\u2022 Option A. Basiliximab directly inhibits the proliferation of T-cells:</li><li>\u2022 Incorrect.</li><li>\u2022 basiliximab</li><li>\u2022 does not</li><li>\u2022 inhibit cell</li><li>\u2022 proliferation;</li><li>\u2022 prevents IL-2</li><li>\u2022 activating T-cells,</li><li>\u2022 indirectly inhibits their proliferation.</li><li>\u2022 Option B. Basiliximab promotes the activation of B-cells: Incorrect. Basiliximab\u2019s action is specific to T-cells and does not involve direct effects on B-cell activation.</li><li>\u2022 Option B. Basiliximab promotes the activation of B-cells:</li><li>\u2022 Incorrect. Basiliximab\u2019s</li><li>\u2022 T-cells</li><li>\u2022 does not</li><li>\u2022 direct effects on B-cell activation.</li><li>\u2022 Option D. Basiliximab enhances the differentiation of dendritic cells: Incorrect . Basiliximab's mechanism of action is centered on T-cells and does not affect the differentiation of dendritic cells.</li><li>\u2022 Option D. Basiliximab enhances the differentiation of dendritic cells:</li><li>\u2022 Incorrect</li><li>\u2022 centered on T-cells</li><li>\u2022 does not</li><li>\u2022 differentiation of dendritic cells.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Basiliximab serves as an immunosuppressant by specifically blocking the IL-2 receptor on activated T-cells , thereby preventing their activation and proliferation. This selective inhibition is critical in preventing organ rejection following transplantation, making basiliximab a valuable therapeutic tool in transplant medicine.</li><li>\u27a4 Basiliximab</li><li>\u27a4 immunosuppressant</li><li>\u27a4 blocking the IL-2 receptor on activated T-cells</li><li>\u27a4 preventing</li><li>\u27a4 activation and proliferation.</li><li>\u27a4 inhibition</li><li>\u27a4 preventing organ rejection</li><li>\u27a4 transplantation,</li><li>\u27a4 basiliximab</li><li>\u27a4 valuable therapeutic</li><li>\u27a4 transplant medicine.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c196d7ea",
      "audio": ""
    },
    {
      "text": "Cetuximab is used for treatment of?",
      "options": [
        {
          "label": "A",
          "text": "Adamantinoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Basal cell Ca",
          "correct": false
        },
        {
          "label": "C",
          "text": "Colorectal Ca",
          "correct": true
        },
        {
          "label": "D",
          "text": "Crohn\u2019s disease",
          "correct": false
        }
      ],
      "correct_answer": "C. Colorectal Ca",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-130406.png"
      ],
      "explanation": "<p><strong>Ans. C) Colorectal Ca</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Adamantinoma: This is a rare type of tumor that typically arises in the bones, specifically the tibia and the jawbone. Cetuximab is not indicated for the treatment of adamantinoma.</li><li>\u2022 Option A. Adamantinoma:</li><li>\u2022 rare</li><li>\u2022 tumor</li><li>\u2022 arises in the bones,</li><li>\u2022 tibia and the jawbone.</li><li>\u2022 Cetuximab</li><li>\u2022 not</li><li>\u2022 treatment of adamantinoma.</li><li>\u2022 Option B. Basal cell Ca (Carcinoma): Basal cell carcinoma is primarily treated with surgical methods, topical treatments, or radiation therapy. Cetuximab is not used for basal cell carcinoma as it generally does not express EGFR to a significant extent.</li><li>\u2022 Option B. Basal cell Ca (Carcinoma):</li><li>\u2022 treated</li><li>\u2022 surgical methods, topical treatments,</li><li>\u2022 radiation</li><li>\u2022 therapy.</li><li>\u2022 Cetuximab</li><li>\u2022 not</li><li>\u2022 basal cell carcinoma</li><li>\u2022 does not</li><li>\u2022 EGFR</li><li>\u2022 Option D. Crohn\u2019s disease: This is an inflammatory bowel disease ; treatment typically involves immunosuppressive and anti-inflammatory agents such as TNF\u03b1 inhibitors (e.g., infliximab). Cetuximab has no role in the treatment of Crohn's disease.</li><li>\u2022 Option D. Crohn\u2019s disease:</li><li>\u2022 inflammatory bowel disease</li><li>\u2022 immunosuppressive</li><li>\u2022 anti-inflammatory agents</li><li>\u2022 TNF\u03b1 inhibitors (e.g., infliximab). Cetuximab</li><li>\u2022 no</li><li>\u2022 treatment of Crohn's disease.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 MONOCLONAL ANTIBODIES</li><li>\u27a4 MONOCLONAL ANTIBODIES</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1983ac02",
      "audio": ""
    },
    {
      "text": "All the following are PD-L1 inhibitors except?",
      "options": [
        {
          "label": "A",
          "text": "Avelumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atezolizumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cetuximab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Durvalumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Cetuximab",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/402.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-131641.png"
      ],
      "explanation": "<p><strong>Ans. C) Cetuximab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Avelumab: Avelumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells. By doing so, it prevents the tumor from evading the immune response, enabling the immune system to attack the cancer cells.</li><li>\u2022 Option A. Avelumab:</li><li>\u2022 PD-L1 inhibitor</li><li>\u2022 blocks the interaction between PD-L1 on tumor cells</li><li>\u2022 PD-1 on T cells.</li><li>\u2022 prevents</li><li>\u2022 tumor</li><li>\u2022 immune response, enabling the immune system</li><li>\u2022 cancer cells.</li><li>\u2022 Option B. Atezolizumab: Similar to Avelumab, Atezolizumab is a monoclonal antibody that binds to PD-L1, inhibiting its interaction with PD-1 . This blockade enhances the body's immune response against tumor cells.</li><li>\u2022 Option B. Atezolizumab:</li><li>\u2022 Avelumab,</li><li>\u2022 monoclonal antibody</li><li>\u2022 PD-L1,</li><li>\u2022 inhibiting</li><li>\u2022 interaction</li><li>\u2022 PD-1</li><li>\u2022 blockade</li><li>\u2022 body's immune response against tumor cells.</li><li>\u2022 Option D. Durvalumab: Durvalumab also targets PD-L1 , preventing it from binding to PD-1. It is part of the group of immune checkpoint inhibitors that help to activate the immune system against cancer cells.</li><li>\u2022 Option D. Durvalumab:</li><li>\u2022 targets PD-L1</li><li>\u2022 preventing</li><li>\u2022 binding to PD-1.</li><li>\u2022 group of immune</li><li>\u2022 checkpoint inhibitors</li><li>\u2022 activate the immune system against cancer cells.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While Avelumab, Atezolizumab, and Durvalumab are all PD-L1 inhibitors enhancing the immune system's ability to fight cancer, Cetuximab works through a different mechanism by targeting EGFR on cancer cells .</li><li>\u27a4 Avelumab, Atezolizumab, and Durvalumab</li><li>\u27a4 all PD-L1 inhibitors</li><li>\u27a4 immune system's ability to fight cancer,</li><li>\u27a4 Cetuximab</li><li>\u27a4 different mechanism</li><li>\u27a4 targeting EGFR on cancer cells</li><li>\u27a4 Immune Check Point inhibitors</li><li>\u27a4 Immune Check Point inhibitors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b412f210",
      "audio": ""
    },
    {
      "text": "Patients undergoing treatment for colorectal cancer have developed symptoms such as tingling, numbness, pain, and erythema on the palms and soles of their feet as shown in the figure below. Which of the following chemotherapy drugs could be the causative agent?",
      "options": [
        {
          "label": "A",
          "text": "Cladribine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gemcitabine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Capecitabine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Bleomycin",
          "correct": false
        }
      ],
      "correct_answer": "C. Capecitabine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/403_RU0SYwK.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Capecitabine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cladribine : Primarily used in hairy cell leukemia, cladribine can cause several side effects but is not typically associated with hand-foot syndrome.</li><li>\u2022 Option A.</li><li>\u2022 Cladribine</li><li>\u2022 used</li><li>\u2022 hairy cell leukemia,</li><li>\u2022 cladribine</li><li>\u2022 several side effects</li><li>\u2022 not</li><li>\u2022 hand-foot syndrome.</li><li>\u2022 Option B. Gemcitabine : Used in various cancers , including pancreatic, breast, and non-small cell lung cancer . While gemcitabine has many side effects, it is less commonly associated with hand-foot syndrome compared to capecitabine.</li><li>\u2022 Option B.</li><li>\u2022 Gemcitabine</li><li>\u2022 various cancers</li><li>\u2022 pancreatic, breast, and non-small cell lung cancer</li><li>\u2022 gemcitabine</li><li>\u2022 side effects,</li><li>\u2022 less</li><li>\u2022 hand-foot syndrome</li><li>\u2022 capecitabine.</li><li>\u2022 Option D. Bleomycin : Used in the treatment of Hodgkin's lymphoma , testicular cancer, and other types of cancer. Bleomycin is more known for pulmonary side effects, and hand-foot syndrome is not a typical side effect of this drug.</li><li>\u2022 Option D.</li><li>\u2022 Bleomycin</li><li>\u2022 treatment of Hodgkin's lymphoma</li><li>\u2022 testicular cancer,</li><li>\u2022 other types of cancer. Bleomycin</li><li>\u2022 more</li><li>\u2022 pulmonary side effects,</li><li>\u2022 hand-foot syndrome</li><li>\u2022 not</li><li>\u2022 typical side effect of this drug.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Capecitabine is the likely cause of the symptoms due to its known association with hand-foot syndrome , particularly in patients treated for colorectal cancer.</li><li>\u27a4 Capecitabine</li><li>\u27a4 known</li><li>\u27a4 hand-foot syndrome</li><li>\u27a4 colorectal cancer.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "002d0945",
      "audio": ""
    },
    {
      "text": "Mechanism of action of two anticancer drugs X and Y is shown in the figure below. Which of following statements most correctly represent drug X and Y?",
      "options": [
        {
          "label": "A",
          "text": "X is 5-Fluorourcail, and Y is Methotrexate",
          "correct": false
        },
        {
          "label": "B",
          "text": "X is Methotrexate and Y is 5-Fluorouracil",
          "correct": true
        },
        {
          "label": "C",
          "text": "X is Vincristine and Y is Methotrexate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Both X and Y are methotrexate",
          "correct": false
        }
      ],
      "correct_answer": "B. X is Methotrexate and Y is 5-Fluorouracil",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/404.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) X is Methotrexate and Y is 5-Fluorouracil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. X is 5-Fluorouracil, and Y is Methotrexate: This is incorrect because 5-FU does not inhibit DHFR but inhibits thymidylate synthase, and Methotrexate inhibits DHFR , not thymidylate synthase.</li><li>\u2022 Option A. X is 5-Fluorouracil, and Y is Methotrexate:</li><li>\u2022 incorrect</li><li>\u2022 5-FU does not inhibit DHFR</li><li>\u2022 inhibits thymidylate</li><li>\u2022 synthase,</li><li>\u2022 Methotrexate inhibits DHFR</li><li>\u2022 not thymidylate synthase.</li><li>\u2022 Option C. X is Vincristine and Y is Methotrexate: Vincristine is a microtubule inhibitor that blocks cell division by inhibiting the formation of the mitotic spindle . It does not inhibit thymidylate synthase or DHFRase. Therefore, option C is incorrect.</li><li>\u2022 Option C.</li><li>\u2022 X is Vincristine and Y is Methotrexate: Vincristine</li><li>\u2022 microtubule inhibitor</li><li>\u2022 blocks cell division</li><li>\u2022 inhibiting the</li><li>\u2022 mitotic spindle</li><li>\u2022 does not</li><li>\u2022 inhibit</li><li>\u2022 synthase or DHFRase.</li><li>\u2022 option C is incorrect.</li><li>\u2022 Option D. Both X and Y are methotrexate: is also incorrect because both X and Y cannot be methotrexate, as they have different targets of action.</li><li>\u2022 Option D. Both X and Y are methotrexate:</li><li>\u2022 incorrect</li><li>\u2022 both X and Y cannot be methotrexate,</li><li>\u2022 different</li><li>\u2022 targets of action.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Methotrexate (Drug X) inhibits the enzyme DHFR, essential for DNA nucleotide synthesis, while 5-Fluorouracil (Drug Y) inhibits thymidylate synthase, critical for the production of the thymidine nucleotide necessary for DNA synthesis.</li><li>\u27a4 Methotrexate (Drug X) inhibits</li><li>\u27a4 DHFR,</li><li>\u27a4 DNA nucleotide synthesis,</li><li>\u27a4 5-Fluorouracil (Drug Y) inhibits</li><li>\u27a4 thymidylate synthase,</li><li>\u27a4 production of the thymidine nucleotide</li><li>\u27a4 DNA synthesis.</li><li>\u27a4 Understanding these targets is key to recognizing the rationale behind using these drugs in the treatment of cancers like leukemia and colorectal cancer, respectively.</li><li>\u27a4 recognizing</li><li>\u27a4 these drugs</li><li>\u27a4 cancers like leukemia</li><li>\u27a4 colorectal cancer, respectively.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dc3d2c33",
      "audio": ""
    },
    {
      "text": "A patient with head and neck cancer was given radiotherapy. After 6 months of radiotherapy, chemotherapy was started but patient presented with the clinical picture as shown after start of chemotherapy. What is the likely drug responsible for this?",
      "options": [
        {
          "label": "A",
          "text": "Doxorubicin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Carboplatin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cetuximab",
          "correct": false
        }
      ],
      "correct_answer": "A. Doxorubicin",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/405.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Doxorubicin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Carboplatin: While Carboplatin can have a variety of side effects, it is less commonly associated with radiation recall syndrome.</li><li>\u2022 Option B. Carboplatin:</li><li>\u2022 Carboplatin</li><li>\u2022 variety of side effects,</li><li>\u2022 less</li><li>\u2022 radiation recall</li><li>\u2022 syndrome.</li><li>\u2022 Option C. Methotrexate: Methotrexate can cause mucositis and skin reactions but is not typically associated with radiation recall.</li><li>\u2022 Option C. Methotrexate:</li><li>\u2022 Methotrexate</li><li>\u2022 mucositis and skin reactions</li><li>\u2022 not</li><li>\u2022 radiation recall.</li><li>\u2022 Option D. Cetuximab: Cetuximab , a monoclonal antibody targeting EGFR, is associated with skin reactions; however, it is not typically cited as a cause of radiation recall syndrome.</li><li>\u2022 Option D. Cetuximab:</li><li>\u2022 Cetuximab</li><li>\u2022 monoclonal antibody targeting EGFR,</li><li>\u2022 skin reactions;</li><li>\u2022 not</li><li>\u2022 typically</li><li>\u2022 cause of radiation recall syndrome.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The most common drugs associated with RRS are anthracyclines (such a s doxorubicin ), taxanes (such as paclitaxel ), and gemcitabine.</li><li>\u27a4 The most common drugs associated with RRS are anthracyclines (such a s doxorubicin ), taxanes (such as paclitaxel ), and gemcitabine.</li><li>\u27a4 most common drugs</li><li>\u27a4 RRS are anthracyclines</li><li>\u27a4 s doxorubicin</li><li>\u27a4 taxanes</li><li>\u27a4 paclitaxel</li><li>\u27a4 gemcitabine.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b71c1ccf",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman presents with a diagnosis of non-Hodgkin's lymphoma. She is started on chemotherapy, which includes a drug derived from the periwinkle plant (Image shown below). Which of the following is the mechanism of action of this drug?",
      "options": [
        {
          "label": "A",
          "text": "Inhibition of microtubule polymerization",
          "correct": true
        },
        {
          "label": "B",
          "text": "Inhibition of DNA synthesis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibition of DNA topoisomerase II",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibition of tyrosine kinase activity",
          "correct": false
        }
      ],
      "correct_answer": "A. Inhibition of microtubule polymerization",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/406.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Inhibition of microtubule polymerization</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Inhibition of DNA synthesis: While some chemotherapeutic agents do inhibit DNA synthesis, the drugs derived from the periwinkle plan t do not act through this mechanism.</li><li>\u2022 Option B. Inhibition of DNA synthesis:</li><li>\u2022 chemotherapeutic agents</li><li>\u2022 inhibit DNA synthesis,</li><li>\u2022 drugs derived</li><li>\u2022 periwinkle plan</li><li>\u2022 do not</li><li>\u2022 mechanism.</li><li>\u2022 Option C. Inhibition of DNA topoisomerase II: This is the mechanism of action for drugs like etoposide , not vinca alkaloids.</li><li>\u2022 Option C. Inhibition of DNA topoisomerase II:</li><li>\u2022 mechanism of action</li><li>\u2022 etoposide</li><li>\u2022 Option D. Inhibition of tyrosine kinase activity: Drugs like imatinib inhibit tyrosine kinase activity and are used for conditions such as chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), which is not the mechanism for vinca alkaloids.</li><li>\u2022 Option D. Inhibition of tyrosine kinase activity:</li><li>\u2022 imatinib inhibit tyrosine kinase activity</li><li>\u2022 chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST),</li><li>\u2022 not</li><li>\u2022 vinca alkaloids.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vinca alkaloids, such as vincristine and vinblastine , work by inhibiting microtubule polymerization, leading to disruption of mitotic spindle formation, cell cycle arrest , and ultimately apoptosis . This mechanism is distinct and should no t be confused with drugs that inhibit DNA synthesis, DNA topoisomerase II, or tyrosine kinase activity.</li><li>\u27a4 Vinca alkaloids,</li><li>\u27a4 vincristine and vinblastine</li><li>\u27a4 inhibiting microtubule polymerization,</li><li>\u27a4 disruption of mitotic</li><li>\u27a4 spindle formation,</li><li>\u27a4 cell cycle arrest</li><li>\u27a4 ultimately apoptosis</li><li>\u27a4 distinct</li><li>\u27a4 should no</li><li>\u27a4 inhibit DNA synthesis, DNA topoisomerase II,</li><li>\u27a4 tyrosine kinase activity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7df2fc75",
      "audio": ""
    },
    {
      "text": "Which of the following anticancer drugs act at the target shown in figure?",
      "options": [
        {
          "label": "A",
          "text": "Erlotinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ribociclib",
          "correct": true
        },
        {
          "label": "C",
          "text": "Dabrafenib",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nilotinib",
          "correct": false
        }
      ],
      "correct_answer": "B. Ribociclib",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/407.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Ribociclib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Erlotinib : Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) pathway . It works by blocking the activity of the EGFR protein, which is often overexpressed in certain types of cancer cells and contributes to tumor growth and spread . Erlotinib is primarily used to treat non-small cell lung cancer and pancreatic cancer.</li><li>\u2022 Option A.</li><li>\u2022 Erlotinib</li><li>\u2022 Erlotinib</li><li>\u2022 tyrosine kinase inhibitor</li><li>\u2022 targets the epidermal growth factor receptor (EGFR) pathway</li><li>\u2022 blocking the activity of the EGFR protein,</li><li>\u2022 overexpressed</li><li>\u2022 cancer cells</li><li>\u2022 tumor growth and spread</li><li>\u2022 Erlotinib</li><li>\u2022 used</li><li>\u2022 non-small cell lung cancer and pancreatic cancer.</li><li>\u2022 Option C. Dabrafenib : Dabrafenib is a selective inhibitor of the BRAF protein , which is a key component of the MAP kinase signalling pathway . This pathway is frequently mutated in certain types of cancer , including melanoma, and drives tumor growth and survival . Dabrafenib is used to treat advanced melanoma with BRAF V600E or V600K mutations</li><li>\u2022 Option C.</li><li>\u2022 Dabrafenib</li><li>\u2022 Dabrafenib</li><li>\u2022 selective inhibitor of the BRAF protein</li><li>\u2022 MAP kinase signalling</li><li>\u2022 pathway</li><li>\u2022 frequently mutated in certain types of cancer</li><li>\u2022 melanoma, and drives tumor growth</li><li>\u2022 and survival</li><li>\u2022 used to treat advanced melanoma</li><li>\u2022 BRAF V600E or V600K mutations</li><li>\u2022 Option D. Nilotinib : Nilotinib is a tyrosine kinase inhibitor that targets the BCR-ABL protein, which is a fusion protein that drives the growth of chronic myelogenous leukemia (CML) cells. It works by blocking the activity of the BCR-ABL protein , leading to inhibition of cell proliferation and induction of cell death . Nilotinib is taken orally and is primarily used to treat CML.</li><li>\u2022 Option D.</li><li>\u2022 Nilotinib</li><li>\u2022 tyrosine kinase inhibitor</li><li>\u2022 BCR-ABL protein,</li><li>\u2022 fusion protein</li><li>\u2022 growth of chronic myelogenous leukemia (CML) cells.</li><li>\u2022 blocking the activity</li><li>\u2022 BCR-ABL protein</li><li>\u2022 inhibition</li><li>\u2022 cell proliferation and induction of cell death</li><li>\u2022 Nilotinib</li><li>\u2022 orally</li><li>\u2022 CML.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Ribociclib is a targeted anticancer therapy that inhibits CDK4/6 , key enzymes in cell cycle regulation . It is used to halt the progression of certain cancers by inducing cell cycle arrest at the G1 phase, thereby impeding the cancer cells from multiplying.</li><li>\u2022 Ribociclib</li><li>\u2022 targeted anticancer</li><li>\u2022 inhibits CDK4/6</li><li>\u2022 cell cycle regulation</li><li>\u2022 used to</li><li>\u2022 progression of certain cancers</li><li>\u2022 inducing cell cycle arrest at the G1 phase,</li><li>\u2022 impeding the cancer cells</li><li>\u2022 from multiplying.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d03c9d2",
      "audio": ""
    },
    {
      "text": "All the following are true about paclitaxel except:",
      "options": [
        {
          "label": "A",
          "text": "Stabilizes microtubules and prevent depolymerization",
          "correct": false
        },
        {
          "label": "B",
          "text": "Used in ovarian, cervix and breast cancer",
          "correct": false
        },
        {
          "label": "C",
          "text": "Most commonly causes myelosuppression and alopecia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Obtained from E. coli",
          "correct": true
        }
      ],
      "correct_answer": "D. Obtained from E. coli",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Obtained from E. coli</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Stabilizes microtubules and prevent polymerization: The statement is almost correct but has a crucial error. Paclitaxel actually stabilizes microtubules but prevents their depolymerization, not polymerization.</li><li>\u2022 Option A. Stabilizes microtubules and prevent polymerization:</li><li>\u2022 correct</li><li>\u2022 crucial error. Paclitaxel</li><li>\u2022 actually stabilizes microtubules</li><li>\u2022 prevents</li><li>\u2022 depolymerization, not polymerization.</li><li>\u2022 Option B. Used in ovarian, cervix and breast cancer: This is true. Paclitaxel is used in the treatment of these cancers due to its effectiveness in inhibiting cell division.</li><li>\u2022 Option B. Used in ovarian, cervix and breast cancer:</li><li>\u2022 true.</li><li>\u2022 Paclitaxel</li><li>\u2022 used</li><li>\u2022 cancers</li><li>\u2022 effectiveness in inhibiting cell division.</li><li>\u2022 Option C. Most commonly causes myelosuppression and alopecia: Also true. These are common side effects of many chemotherapeutic agents , including paclitaxel.</li><li>\u2022 Option C. Most commonly causes myelosuppression and alopecia:</li><li>\u2022 true.</li><li>\u2022 common side effects</li><li>\u2022 many</li><li>\u2022 chemotherapeutic agents</li><li>\u2022 paclitaxel.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Paclitaxel , a chemotherapeutic agent that is known for its ability to stabilize microtubules and thereby prevent their depolymerization , leading to inhibition of cell division in cancer treatment. It is associated with side effects such as myelosuppression and alopecia; and it was originally obtained from the bark of the Pacific yew tree and now can be produced synthetically.</li><li>\u2022 Paclitaxel</li><li>\u2022 chemotherapeutic agent</li><li>\u2022 known</li><li>\u2022 ability to stabilize microtubules</li><li>\u2022 prevent their</li><li>\u2022 depolymerization</li><li>\u2022 inhibition of cell division</li><li>\u2022 cancer treatment.</li><li>\u2022 side effects</li><li>\u2022 myelosuppression and alopecia;</li><li>\u2022 originally</li><li>\u2022 bark of the Pacific yew tree</li><li>\u2022 produced</li><li>\u2022 synthetically.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c068f64f",
      "audio": ""
    },
    {
      "text": "Bortezomib is a drug used for treatment of multiple myeloma. What is the mechanism of action of this drug?",
      "options": [
        {
          "label": "A",
          "text": "mTOR inhibitor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Proteasome inhibitor",
          "correct": true
        },
        {
          "label": "C",
          "text": "Histone deacetylase inhibitors",
          "correct": false
        },
        {
          "label": "D",
          "text": "Protein tyrosine kinase inhibitor",
          "correct": false
        }
      ],
      "correct_answer": "B. Proteasome inhibitor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Proteasome inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. mTOR inhibitor : The mammalian target of rapamycin (mTOR) is a protein kinase that plays a key role in regulating cell growth and proliferation. Inhibition of mTOR activity can slow down or stop the growth of cancer cells. mTOR inhibitors such as temsirolimus and everolimus are used to treat renal cell carcinoma and breast cancer.</li><li>\u2022 Option A.</li><li>\u2022 mTOR inhibitor</li><li>\u2022 mammalian target of rapamycin (mTOR)</li><li>\u2022 protein kinase</li><li>\u2022 regulating cell</li><li>\u2022 growth and proliferation.</li><li>\u2022 Inhibition of mTOR activity</li><li>\u2022 slow down</li><li>\u2022 stop the growth of cancer cells.</li><li>\u2022 mTOR inhibitors</li><li>\u2022 temsirolimus and everolimus</li><li>\u2022 treat renal cell carcinoma</li><li>\u2022 breast cancer.</li><li>\u2022 Option C. Histone deacetylase inhibitors : HDAC enzymes are involved in the regulation of gene expression . By altering the acetylation status of histone proteins , HDAC inhibitors can induce changes in gene expression that can lead to cell cycle arrest, differentiation, or apoptosis. These drugs are used to treat various types of cancer, including lymphoma and leukaemia. Examples of HDAC inhibitors include vorinostat, romidepsin, and belinostat.</li><li>\u2022 Option C.</li><li>\u2022 Histone deacetylase inhibitors</li><li>\u2022 regulation of gene expression</li><li>\u2022 altering</li><li>\u2022 acetylation status of histone proteins</li><li>\u2022 HDAC inhibitors</li><li>\u2022 gene expression</li><li>\u2022 cell cycle arrest,</li><li>\u2022 differentiation, or apoptosis.</li><li>\u2022 used</li><li>\u2022 cancer,</li><li>\u2022 lymphoma and leukaemia.</li><li>\u2022 HDAC inhibitors</li><li>\u2022 vorinostat, romidepsin, and belinostat.</li><li>\u2022 Option D. Protein tyrosine kinase inhibitor : Protein tyrosine kinases (PTKs) are enzymes that play a role in cell signaling pathways and are often overexpressed or mutated in cancer cells . PTK inhibitors such as imatinib, dasatinib, and erlotinib target specific tyrosine kinases and inhibit their activity, leading to decreased cell proliferation and survival . These drugs are used to treat various types of cancer, including chronic myelogenous leukemia (CML) and some forms of lung cancer.</li><li>\u2022 Option D.</li><li>\u2022 Protein tyrosine kinase inhibitor</li><li>\u2022 Protein tyrosine kinases (PTKs)</li><li>\u2022 cell signaling pathways</li><li>\u2022 overexpressed or mutated in cancer cells</li><li>\u2022 PTK inhibitors</li><li>\u2022 imatinib, dasatinib, and erlotinib</li><li>\u2022 target specific</li><li>\u2022 tyrosine kinases</li><li>\u2022 inhibit their activity,</li><li>\u2022 decreased cell proliferation and survival</li><li>\u2022 used to treat</li><li>\u2022 types of cancer,</li><li>\u2022 chronic myelogenous leukemia (CML)</li><li>\u2022 lung cancer.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bortezomib's role as a proteasome inhibitor makes it an effective drug in the treatment of multiple myeloma, by disrupting the regulated degradation of proteins and causing a build-up that is toxic to cancer cells.</li><li>\u27a4 Bortezomib's</li><li>\u27a4 proteasome inhibitor</li><li>\u27a4 effective drug</li><li>\u27a4 multiple myeloma,</li><li>\u27a4 disrupting</li><li>\u27a4 regulated degradation of proteins</li><li>\u27a4 build-up that is toxic to cancer cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e6265eae",
      "audio": ""
    },
    {
      "text": "Which is not a radiosensitizer?",
      "options": [
        {
          "label": "A",
          "text": "Amifostine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hydroxyurea",
          "correct": false
        },
        {
          "label": "C",
          "text": "5FU",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bromodeoxyuridine",
          "correct": false
        }
      ],
      "correct_answer": "A. Amifostine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-143815.png"
      ],
      "explanation": "<p><strong>Ans. A) Amifostine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Hydroxyurea: Hydroxyurea acts as a radiosensitizer by inhibiting the enzyme ribonucleotide reductase, which leads to a depletion of deoxyribonucleotides and thereby enhances the effects of radiation on cancer cells.</li><li>\u2022 Option B. Hydroxyurea:</li><li>\u2022 radiosensitizer</li><li>\u2022 inhibiting the enzyme ribonucleotide reductase,</li><li>\u2022 depletion of deoxyribonucleotides</li><li>\u2022 enhances the effects of radiation on cancer cells.</li><li>\u2022 Option C. 5FU (5-Fluorouracil): 5FU is a chemotherapy agent that also functions as a radiosensitizer. It is incorporated into RNA and DNA and interfere s with the synthesis and function of nucleic acids , enhancing radiation therapy's efficacy.</li><li>\u2022 Option C. 5FU (5-Fluorouracil):</li><li>\u2022 5FU</li><li>\u2022 chemotherapy agent</li><li>\u2022 radiosensitizer.</li><li>\u2022 incorporated</li><li>\u2022 RNA</li><li>\u2022 DNA</li><li>\u2022 interfere</li><li>\u2022 synthesis</li><li>\u2022 function of nucleic acids</li><li>\u2022 enhancing radiation therapy's efficacy.</li><li>\u2022 Option D. Bromodeoxyuridine: This is a thymidine analog that is incorporated into DNA during the S-phase of the cell cycle , making DNA more susceptible to damage by radiation.</li><li>\u2022 Option D. Bromodeoxyuridine:</li><li>\u2022 thymidine analog</li><li>\u2022 incorporated into DNA</li><li>\u2022 S-phase of the cell cycle</li><li>\u2022 DNA more</li><li>\u2022 damage by radiation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 key differences between radiosensitizers and radioprotectors:</li><li>\u27a4 key differences between radiosensitizers and radioprotectors:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4828261b",
      "audio": ""
    },
    {
      "text": "A 32-year-old female presents to the clinic with a complaint of a rash on her arms and legs that has been present for the past few weeks. She reports feeling fatigued and has been experiencing intermittent fevers. The patient has a history of Hodgkin's lymphoma and underwent chemotherapy treatment approximately two months ago. Her chemotherapy regimen included daunorubicin, bleomycin, and vincristine. On physical examination, the patient is noted to have multiple erythematous, linear lesions on her arms and legs that appear to be hyperpigmented in a flagellate pattern. The remainder of her examination is unremarkable. Based on the patient's clinical history and examination, which drug is most likely responsible for her skin pigmentation?",
      "options": [
        {
          "label": "A",
          "text": "Bleomycin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Minocycline",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vincristine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Daunorubicin",
          "correct": false
        }
      ],
      "correct_answer": "A. Bleomycin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/409.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Bleomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Minocycline: This is an antibiotic that can cause various types of skin hyperpigmentation , but these usually take the form of blue-gray spots or diffuse pigmentation, particularly in areas of previous inflammation or sun exposure . It is not known to cause the flagellate or whip-like streaking pattern associated with Bleomycin.</li><li>\u2022 Option B. Minocycline:</li><li>\u2022 antibiotic</li><li>\u2022 skin hyperpigmentation</li><li>\u2022 blue-gray spots or diffuse pigmentation, particularly</li><li>\u2022 previous inflammation or sun exposure</li><li>\u2022 not</li><li>\u2022 flagellate or whip-like streaking pattern</li><li>\u2022 with Bleomycin.</li><li>\u2022 Option C. Vincristine: While Vincristine is a chemotherapeutic agent used in the same types of cancer as Bleomycin , its side effect profile includes neurological symptoms such as peripheral neuropathy, rather than dermatological condition s like flagellate pigmentation. The presentation of such a specific skin reaction does not align with the known adverse effects of Vincristine.</li><li>\u2022 Option C. Vincristine:</li><li>\u2022 Vincristine</li><li>\u2022 chemotherapeutic agent</li><li>\u2022 same types of cancer</li><li>\u2022 Bleomycin</li><li>\u2022 side effect</li><li>\u2022 neurological symptoms</li><li>\u2022 peripheral neuropathy,</li><li>\u2022 dermatological condition</li><li>\u2022 flagellate</li><li>\u2022 pigmentation.</li><li>\u2022 presentation</li><li>\u2022 specific skin reaction does not</li><li>\u2022 known adverse effects of Vincristine.</li><li>\u2022 Option D. Daunorubicin: As an anthracycline chemotherapeutic , Daunorubicin can cause a variety of side effects, with the most prominent being myelosuppression. It can also lead to cardiotoxicity with long-term use . However, it is not implicated in causing the characteristic flagellate pigmentation that is seen with Bleomycin therapy.</li><li>\u2022 Option D. Daunorubicin:</li><li>\u2022 anthracycline chemotherapeutic</li><li>\u2022 Daunorubicin</li><li>\u2022 variety of side effects,</li><li>\u2022 prominent being myelosuppression.</li><li>\u2022 lead to cardiotoxicity</li><li>\u2022 long-term use</li><li>\u2022 not</li><li>\u2022 flagellate pigmentation</li><li>\u2022 seen with Bleomycin therapy.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bleomycin can lead to flagellate pigmentation , a distinct dermatologic reaction characterized by whip-like hyperpigmented streaks . This adverse effect should be recognized by healthcare providers as a potential delayed side effect of the drug, particularly in patients with a history of cancer treatment including Bleomycin.</li><li>\u27a4 Bleomycin</li><li>\u27a4 flagellate pigmentation</li><li>\u27a4 distinct dermatologic reaction</li><li>\u27a4 whip-like hyperpigmented streaks</li><li>\u27a4 adverse effect</li><li>\u27a4 healthcare providers</li><li>\u27a4 potential delayed side effect of the drug,</li><li>\u27a4 patients with a history of cancer</li><li>\u27a4 Bleomycin.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "14cadfda",
      "audio": ""
    },
    {
      "text": "All the following statements are true about tacrolimus except:",
      "options": [
        {
          "label": "A",
          "text": "It is a macrolide lactone",
          "correct": false
        },
        {
          "label": "B",
          "text": "It inhibits the gene transcription of interleukin 2",
          "correct": false
        },
        {
          "label": "C",
          "text": "It acts by binding to immunophilins",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hirsutism is more common than cyclosporine",
          "correct": true
        }
      ],
      "correct_answer": "D. Hirsutism is more common than cyclosporine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hirsutism is more common than cyclosporine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is a macrolide lactone: True . Tacrolimus is a macrolide lactone ; it is structurally similar to other macrolides like erythromycin and azithromycin but has a different function, primarily as an immunosuppressant.</li><li>\u2022 Option A. It is a macrolide lactone:</li><li>\u2022 True</li><li>\u2022 Tacrolimus is a macrolide lactone</li><li>\u2022 other macrolides</li><li>\u2022 erythromycin and azithromycin</li><li>\u2022 different function, primarily as an immunosuppressant.</li><li>\u2022 Option B. It inhibits the gene transcription of interleukin 2: True . Tacrolimus i nhibits the activation of T-lymphocytes by inhibiting calcineurin , which in turn reduces the transcription of interleukin-2 (IL-2). IL-2 is critical for the growth and activation of T-cells , so its suppression is key to tacrolimus's ability to prevent organ rejection in transplant patients.</li><li>\u2022 Option B. It inhibits the gene transcription of interleukin 2:</li><li>\u2022 True</li><li>\u2022 Tacrolimus</li><li>\u2022 nhibits the activation of T-lymphocytes</li><li>\u2022 inhibiting</li><li>\u2022 calcineurin</li><li>\u2022 reduces the transcription of interleukin-2 (IL-2).</li><li>\u2022 growth and activation of T-cells</li><li>\u2022 suppression</li><li>\u2022 tacrolimus's ability</li><li>\u2022 prevent organ rejection</li><li>\u2022 transplant patients.</li><li>\u2022 Option C. It acts by binding to immunophilins: True . Tacrolimus binds specifically to the immunophilin known as FK506 binding protein (FKBP) , forming a complex that inhibits calcineurin, a necessary enzyme in the T-cell activation pathway. This action is crucial for its immunosuppressive effects.</li><li>\u2022 Option C. It acts by binding to immunophilins:</li><li>\u2022 True</li><li>\u2022 Tacrolimus</li><li>\u2022 immunophilin</li><li>\u2022 FK506 binding</li><li>\u2022 protein (FKBP)</li><li>\u2022 complex</li><li>\u2022 inhibits calcineurin,</li><li>\u2022 T-cell activation pathway.</li><li>\u2022 its immunosuppressive effects.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While tacrolimus shares some mechanisms of action with other immunosuppressants like cyclosporine, notably its suppression of T-cell activation via calcineurin inhibition , it does not cause hirsutism as commonly as cyclosporine does. This distinction is important in clinical practice when choosing an immunosuppressant , especially considering the side effect profiles that can affect patient compliance and quality of life.</li><li>\u27a4 tacrolimus</li><li>\u27a4 mechanisms of action</li><li>\u27a4 other immunosuppressants</li><li>\u27a4 cyclosporine,</li><li>\u27a4 suppression of T-cell activation</li><li>\u27a4 calcineurin inhibition</li><li>\u27a4 does not</li><li>\u27a4 hirsutism</li><li>\u27a4 clinical practice</li><li>\u27a4 immunosuppressant</li><li>\u27a4 side effect</li><li>\u27a4 patient compliance and quality of life.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b2882382",
      "audio": ""
    },
    {
      "text": "A 56-year-old man presents to the oncology clinic with a 6-month history of progressively worsening headaches and nausea. He has no significant past medical history. MRI reveals a large, heterogeneously enhancing mass in the right frontal lobe. Biopsy confirms the diagnosis of glioblastoma multiforme. The patient is started on temozolomide. What is the mechanism of action of temozolomide?",
      "options": [
        {
          "label": "A",
          "text": "Alkylation of DNA",
          "correct": true
        },
        {
          "label": "B",
          "text": "Crosslinking of DNA",
          "correct": false
        },
        {
          "label": "C",
          "text": "Microtubule inhibition",
          "correct": false
        },
        {
          "label": "D",
          "text": "Proteosome inhibition",
          "correct": false
        }
      ],
      "correct_answer": "A. Alkylation of DNA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Alkylation of DNA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Crosslinking of DNA: Incorrect for temozolomide. Crosslinking of DNA strands is characteristic of platinum-based chemotherapeutic agents such as cisplatin and carboplatin , which form covalent bonds between adjacent guanine bases, thereby preventing DNA from being unwound for replication or transcription.</li><li>\u2022 Option B. Crosslinking of DNA:</li><li>\u2022 Incorrect</li><li>\u2022 Crosslinking of DNA strands</li><li>\u2022 platinum-based</li><li>\u2022 chemotherapeutic</li><li>\u2022 cisplatin and carboplatin</li><li>\u2022 covalent bonds between adjacent guanine bases,</li><li>\u2022 preventing DNA</li><li>\u2022 unwound for replication or transcription.</li><li>\u2022 Option C. Microtubule inhibition: Incorrect for temozolomide. Microtubule inhibitors like paclitaxel and vinblastine disrupt microtubule dynamics , which are critical for cell division , particularly during mitosis.</li><li>\u2022 Option C. Microtubule inhibition:</li><li>\u2022 Incorrect</li><li>\u2022 Microtubule inhibitors</li><li>\u2022 paclitaxel and vinblastine</li><li>\u2022 disrupt</li><li>\u2022 microtubule dynamics</li><li>\u2022 cell division</li><li>\u2022 mitosis.</li><li>\u2022 Option D. Proteosome inhibition: Incorrect for temozolomide. Proteosome inhibitors , such as bortezomib and carfilzomib, block the proteasome's role in degrading misfolded proteins , which causes an accumulation of defective proteins and induces apoptosis in cancer cells.</li><li>\u2022 Option D. Proteosome inhibition:</li><li>\u2022 Incorrect</li><li>\u2022 Proteosome inhibitors</li><li>\u2022 bortezomib and carfilzomib,</li><li>\u2022 block</li><li>\u2022 proteasome's</li><li>\u2022 degrading misfolded proteins</li><li>\u2022 defective proteins</li><li>\u2022 induces apoptosis</li><li>\u2022 cancer cells.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Temozolomide's mechanism of action as a DNA alkylating agent makes it effective in treating glioblastoma multiforme by inducing lethal DNA damage in the rapidly dividing tumor cells . This action highlights the importance of DNA integrity in cell survival and the therapeutic targeting of DNA repair mechanisms in cancer treatment.</li><li>\u27a4 Temozolomide's</li><li>\u27a4 DNA alkylating agent</li><li>\u27a4 effective in treating glioblastoma multiforme</li><li>\u27a4 lethal DNA damage</li><li>\u27a4 rapidly dividing tumor cells</li><li>\u27a4 importance of DNA integrity in cell survival</li><li>\u27a4 therapeutic targeting of DNA repair</li><li>\u27a4 cancer treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9930948a",
      "audio": ""
    },
    {
      "text": "Monoclonal antibody used in Head and Neck cancer is?",
      "options": [
        {
          "label": "A",
          "text": "Pembrolizumab",
          "correct": true
        },
        {
          "label": "B",
          "text": "Trastuzumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ocrelizumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Pembrolizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Pembrolizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Trastuzumab : Trastuzumab is a monoclonal antibody that is used to treat HER2-positive breast cancer, which is a type of breast cancer that has high levels of the protein HER2 on the surface of the cancer cells.</li><li>\u2022 Option B.</li><li>\u2022 Trastuzumab</li><li>\u2022 monoclonal antibody</li><li>\u2022 used</li><li>\u2022 HER2-positive breast cancer,</li><li>\u2022 breast cancer</li><li>\u2022 high levels of the protein HER2</li><li>\u2022 surface</li><li>\u2022 cancer cells.</li><li>\u2022 Option C. Rituximab : Rituximab is a monoclonal antibody that is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis . It works by targeting a protein called CD20 on the surface of B cells , which are a type of immune cell that can become cancerous in certain conditions.</li><li>\u2022 Option C.</li><li>\u2022 Rituximab</li><li>\u2022 monoclonal antibody</li><li>\u2022 chronic lymphocytic</li><li>\u2022 leukemia, and rheumatoid arthritis</li><li>\u2022 targeting a protein</li><li>\u2022 CD20</li><li>\u2022 surface of B cells</li><li>\u2022 immune cell</li><li>\u2022 cancerous</li><li>\u2022 Option D. Ocrelizumab : Ocrelizumab is a monoclonal antibody that is used to treat multiple sclerosis, a chronic autoimmune disease that affects the central nervous system . It targets a protein called CD20 on B cells, which are thought to play a role in the development of the disease.</li><li>\u2022 Option D.</li><li>\u2022 Ocrelizumab</li><li>\u2022 monoclonal antibody</li><li>\u2022 used to treat multiple sclerosis, a chronic autoimmune disease</li><li>\u2022 central nervous system</li><li>\u2022 targets a protein</li><li>\u2022 CD20 on B cells,</li><li>\u2022 development of the disease.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pembrolizumab is utilized in the treatment of head and neck cancer due to its ability to enhance the immune response against cancer cells by inhibiting the PD-1 pathway . This action helps to counteract the immune evasion tactics employed by many cancers, highlighting the importance of immune checkpoint inhibitors in modern oncology.</li><li>\u27a4 Pembrolizumab</li><li>\u27a4 head and neck cancer</li><li>\u27a4 enhance</li><li>\u27a4 immune response</li><li>\u27a4 cancer cells by inhibiting the PD-1 pathway</li><li>\u27a4 helps to counteract the immune evasion tactics</li><li>\u27a4 cancers,</li><li>\u27a4 highlighting</li><li>\u27a4 immune checkpoint inhibitors</li><li>\u27a4 modern oncology.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d62d88ab",
      "audio": ""
    },
    {
      "text": "A 40-year-old male was on treatment with MOPP regimen for Hodgkin\u2019s lymphoma. He recently attended a party and had bouts of alcohol with his friends. Soon after, he started experiencing flushing of the face, headache, nausea, vomiting, chest pain, weakness, blurred vision, mental confusion, sweating, choking, breathing difficulty, and anxiety. These effects began about 10 minutes after drinking and lasted for 1 hour. What drug is likely to cause this presentation?",
      "options": [
        {
          "label": "A",
          "text": "Mechlorethamine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oncovin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Procarbazine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Prednisone",
          "correct": false
        }
      ],
      "correct_answer": "C. Procarbazine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-145325.png"
      ],
      "explanation": "<p><strong>Ans. C) Procarbazine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mechlorethamine: Also part of the MOPP regimen, mechlorethamine is an alkylating agent that causes DNA crosslinks but does not induce a disulfiram-like reaction with alcohol.</li><li>\u2022 Option A. Mechlorethamine:</li><li>\u2022 MOPP regimen,</li><li>\u2022 alkylating agent</li><li>\u2022 DNA crosslinks</li><li>\u2022 does not</li><li>\u2022 disulfiram-like reaction with alcohol.</li><li>\u2022 Option B. Oncovin (Vincristine): Vincristine is a chemotherapeutic agent that inhibits microtubule formation . It does not interact with alcohol to produce disulfiram-like reactions.</li><li>\u2022 Option B. Oncovin (Vincristine):</li><li>\u2022 chemotherapeutic agent</li><li>\u2022 inhibits microtubule formation</li><li>\u2022 does not</li><li>\u2022 alcohol</li><li>\u2022 disulfiram-like reactions.</li><li>\u2022 Option D. Prednisone: A corticosteroid used in various chemotherapy regimens, including MOPP, prednisone has many effects on metabolism and the immune system but does not cause disulfiram-like reactions when combined with alcohol.</li><li>\u2022 Option D. Prednisone:</li><li>\u2022 corticosteroid</li><li>\u2022 chemotherapy regimens,</li><li>\u2022 MOPP, prednisone</li><li>\u2022 metabolism and the immune system</li><li>\u2022 does not</li><li>\u2022 disulfiram-like reactions</li><li>\u2022 alcohol.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Procarbazine can induce a disulfiram-like reaction when taken with alcohol, manifesting as severe and acute symptoms shortly after alcohol consumption. It is crucial for patients receiving procarbazine to avoid alcohol to prevent these potentially distressing and dangerous effects.</li><li>\u27a4 Procarbazine</li><li>\u27a4 disulfiram-like reaction</li><li>\u27a4 taken</li><li>\u27a4 alcohol,</li><li>\u27a4 severe and acute symptoms</li><li>\u27a4 crucial for patients</li><li>\u27a4 procarbazine</li><li>\u27a4 avoid alcohol to prevent</li><li>\u27a4 distressing</li><li>\u27a4 and dangerous effects.</li><li>\u27a4 Drugs causing disulfiram like reaction:</li><li>\u27a4 Drugs causing disulfiram like reaction:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9e255ee0",
      "audio": ""
    },
    {
      "text": "All are monoclonal antibodies approved for use in psoriasis, Except:",
      "options": [
        {
          "label": "A",
          "text": "Ustekinumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Brodalumab",
          "correct": false
        },
        {
          "label": "C",
          "text": "Secukinumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sarilumab",
          "correct": true
        }
      ],
      "correct_answer": "D. Sarilumab",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-150951.png"
      ],
      "explanation": "<p><strong>Ans. D) Sarilumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ustekinumab: This monoclonal antibody targets both interleukin-12 (IL-12) and interleukin-23 (IL-23). It is approved for the treatment of psoriasis, psoriatic arthritis, and Crohn's disease. It works by modulating the immune response that contributes to the inflammation characteristic of these conditions.</li><li>\u2022 Option A. Ustekinumab:</li><li>\u2022 monoclonal antibody</li><li>\u2022 interleukin-12 (IL-12) and interleukin-23 (IL-23).</li><li>\u2022 psoriasis, psoriatic arthritis, and Crohn's disease.</li><li>\u2022 modulating the immune response</li><li>\u2022 inflammation</li><li>\u2022 Option B. Brodalumab: Targets the interleukin-17 (IL-17) receptor, approved for the treatment of psoriasis. By blocking IL-17, Brodalumab helps reduce inflammation and the rapid skin cell turnover associated with psoriasis.</li><li>\u2022 Option B. Brodalumab:</li><li>\u2022 Targets</li><li>\u2022 interleukin-17 (IL-17) receptor,</li><li>\u2022 psoriasis.</li><li>\u2022 blocking IL-17,</li><li>\u2022 Brodalumab</li><li>\u2022 reduce inflammation</li><li>\u2022 rapid skin cell</li><li>\u2022 psoriasis.</li><li>\u2022 Option C. Secukinumab: This antibody targets interleukin-17A (IL-17A) and is approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis . It works similarly to Brodalumab by targeting a key cytokine involved in inflammatory processes</li><li>\u2022 Option C. Secukinumab:</li><li>\u2022 antibody targets interleukin-17A (IL-17A)</li><li>\u2022 psoriasis, psoriatic arthritis,</li><li>\u2022 ankylosing spondylitis</li><li>\u2022 Brodalumab</li><li>\u2022 cytokine</li><li>\u2022 inflammatory processes</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While Ustekinumab, Brodalumab, and Secukinumab are approved and effective treatments for psoriasis through their targeting of specific interleukins involved in inflammatory pathways, Sarilumab, though a monoclonal antibody , is not used for psoriasis as it targets IL-6 , relevant primarily in the context of rheumatoid arthritis.</li><li>\u27a4 Ustekinumab, Brodalumab, and Secukinumab</li><li>\u27a4 approved</li><li>\u27a4 effective</li><li>\u27a4 psoriasis</li><li>\u27a4 targeting</li><li>\u27a4 specific interleukins</li><li>\u27a4 inflammatory pathways,</li><li>\u27a4 Sarilumab,</li><li>\u27a4 monoclonal antibody</li><li>\u27a4 not</li><li>\u27a4 psoriasis</li><li>\u27a4 targets IL-6</li><li>\u27a4 relevant primarily</li><li>\u27a4 rheumatoid arthritis.</li><li>\u27a4 Monoclonal antibodies for psoriasis:</li><li>\u27a4 Monoclonal antibodies for psoriasis:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "28f46f84",
      "audio": ""
    },
    {
      "text": "Pulmonary fibrosis is an adverse effect of which of the following anti-cancer drugs?",
      "options": [
        {
          "label": "A",
          "text": "Mitomycin C",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hydroxyurea",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bleomycin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Cisplatin",
          "correct": false
        }
      ],
      "correct_answer": "C. Bleomycin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/05/whatsapp-image-2024-02-05-at-180437_nS2gu6G.jpeg"
      ],
      "explanation": "<p><strong>Ans. C) Bleomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mitomycin C : This is an alkylating agent used in cancer chemotherapy. Its common side effects include bone marrow suppression, nausea, vomiting, and renal toxicity, but it is not primarily known for causing pulmonary fibrosis.</li><li>\u2022 Option A.</li><li>\u2022 Mitomycin C</li><li>\u2022 alkylating agent</li><li>\u2022 cancer chemotherapy.</li><li>\u2022 side effects</li><li>\u2022 bone marrow</li><li>\u2022 suppression, nausea, vomiting, and renal toxicity,</li><li>\u2022 not</li><li>\u2022 causing pulmonary fibrosis.</li><li>\u2022 Option B. Hydroxyurea : This medication is used for various myeloproliferative disorders and sickle cell disease. Its side effects often include bone marrow suppression and gastrointestinal symptoms, but it is not typically associated with pulmonary fibrosis.</li><li>\u2022 Option B.</li><li>\u2022 Hydroxyurea</li><li>\u2022 used for</li><li>\u2022 myeloproliferative disorders</li><li>\u2022 sickle cell disease.</li><li>\u2022 side effects</li><li>\u2022 bone marrow suppression and gastrointestinal symptoms,</li><li>\u2022 not</li><li>\u2022 pulmonary fibrosis.</li><li>\u2022 Option D. Cisplatin : A platinum-containing chemotherapy drug used to treat various types of cancers. While nephrotoxicity (kidney damage) and ototoxicity (hearing damage) are common adverse effects, it is not typically associated with pulmonary fibrosis.</li><li>\u2022 Option D.</li><li>\u2022 Cisplatin</li><li>\u2022 platinum-containing chemotherapy</li><li>\u2022 used to</li><li>\u2022 types of cancers.</li><li>\u2022 nephrotoxicity (kidney</li><li>\u2022 damage) and ototoxicity (hearing damage)</li><li>\u2022 not</li><li>\u2022 pulmonary fibrosis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bleomycin is known to cause pulmonary fibrosis , which is a condition characterized by the scarring and thickening of lung tissue.</li><li>\u27a4 Bleomycin</li><li>\u27a4 pulmonary fibrosis</li><li>\u27a4 scarring and thickening of lung tissue.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c98fde8b",
      "audio": ""
    },
    {
      "text": "Which of the following Tyrosine kinase inhibitors is used for the treatment of malignant melanoma?",
      "options": [
        {
          "label": "A",
          "text": "Erlotinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Regorafenib",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sorafenib",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vemurafenib",
          "correct": true
        }
      ],
      "correct_answer": "D. Vemurafenib",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-151648.png"
      ],
      "explanation": "<p><strong>Ans. D) Vemurafenib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Erlotinib: Erlotinib is used primarily for non-small cell lung carcinoma (NSCLC) and pancreatic cancer. It targets the epidermal growth factor receptor (EGFR), which is overexpressed or mutated in these cancers.</li><li>\u2022 Option A. Erlotinib:</li><li>\u2022 non-small cell lung carcinoma (NSCLC)</li><li>\u2022 pancreatic cancer.</li><li>\u2022 targets</li><li>\u2022 epidermal growth factor receptor (EGFR),</li><li>\u2022 overexpressed or mutated</li><li>\u2022 Option B. Regorafenib: Regorafenib is used for colorectal carcinoma and gastrointestinal stromal tumors (GIST). It inhibits multiple protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment.</li><li>\u2022 Option B. Regorafenib:</li><li>\u2022 colorectal carcinoma and gastrointestinal stromal tumors (GIST).</li><li>\u2022 inhibits</li><li>\u2022 protein kinases</li><li>\u2022 tumor angiogenesis, oncogenesis,</li><li>\u2022 tumor microenvironment.</li><li>\u2022 Option C. Sorafenib: Sorafenib is used mainly for hepatocellular carcinoma (HCC) and also for renal cell carcinoma (RCC) . It targets multiple kinases , including those involved in angiogenesis and cell proliferation.</li><li>\u2022 Option C. Sorafenib:</li><li>\u2022 hepatocellular carcinoma (HCC)</li><li>\u2022 renal cell carcinoma (RCC)</li><li>\u2022 targets</li><li>\u2022 multiple kinases</li><li>\u2022 angiogenesis and cell proliferation.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Vemurafenib is used for the treatment of malignant melanoma. Erlotinib is used for  non-small cell carcinoma of lung and pancreatic carcinoma. Regorafenib is used for colorectal carcinoma and GIST. Sorafenib is used for hepatocellular carcinoma.</li><li>\u2022 Vemurafenib is used for the treatment of malignant melanoma.</li><li>\u2022 Vemurafenib</li><li>\u2022 used for</li><li>\u2022 malignant melanoma.</li><li>\u2022 Erlotinib is used for  non-small cell carcinoma of lung and pancreatic carcinoma.</li><li>\u2022 Erlotinib</li><li>\u2022 used for  non-small cell carcinoma of lung and pancreatic carcinoma.</li><li>\u2022 Regorafenib is used for colorectal carcinoma and GIST.</li><li>\u2022 Regorafenib</li><li>\u2022 colorectal carcinoma and GIST.</li><li>\u2022 Sorafenib is used for hepatocellular carcinoma.</li><li>\u2022 Sorafenib</li><li>\u2022 hepatocellular carcinoma.</li><li>\u2022 Indications of tyrosine kinase inhibitors</li><li>\u2022 Indications of tyrosine kinase inhibitors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "136ba298",
      "audio": ""
    },
    {
      "text": "Pharyngolaryngeal dysesthesia is a peculiar side effect of which of the following drugs?",
      "options": [
        {
          "label": "A",
          "text": "Cisplatin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carboplatin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oxaliplatin",
          "correct": true
        },
        {
          "label": "D",
          "text": "All the platinum compounds",
          "correct": false
        }
      ],
      "correct_answer": "C. Oxaliplatin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Oxaliplatin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Cisplatin: While Cisplatin is associated with various side effects, including nephrotoxicity and ototoxicity, pharyngolaryngeal dysesthesia is not commonly seen with this medication.</li><li>\u2022 Option A. Cisplatin:</li><li>\u2022 side effects,</li><li>\u2022 nephrotoxicity and ototoxicity,</li><li>\u2022 pharyngolaryngeal dysesthesia</li><li>\u2022 not</li><li>\u2022 seen</li><li>\u2022 medication.</li><li>\u2022 Option B. Carboplatin: Carboplatin, another platinum-based chemotherapeutic agent , tends to have a different side effect profile , and pharyngolaryngeal dysesthesia is not a characteristic side effect.</li><li>\u2022 Option B. Carboplatin:</li><li>\u2022 another platinum-based chemotherapeutic agent</li><li>\u2022 different side effect profile</li><li>\u2022 pharyngolaryngeal dysesthesia</li><li>\u2022 not</li><li>\u2022 side effect.</li><li>\u2022 Option D. All the platinum compounds: This option is too broad. While all platinum compounds have side effects r elated to their cytotoxicity, pharyngolaryngeal dysesthesia is specific to Oxaliplatin and is not generally seen with other platinum-based chemotherapeutic agents.</li><li>\u2022 Option D. All the platinum compounds:</li><li>\u2022 all platinum compounds</li><li>\u2022 side effects r</li><li>\u2022 cytotoxicity, pharyngolaryngeal dysesthesia</li><li>\u2022 Oxaliplatin</li><li>\u2022 not</li><li>\u2022 seen</li><li>\u2022 other platinum-based</li><li>\u2022 chemotherapeutic agents.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When patients receiving chemotherapy with Oxaliplatin report unusual sensations in the throat and laryngeal area , especially in response to cold, it is likely due to pharyngolaryngeal dysesthesia . It's important for clinicians to be aware of this potential side effect and to counsel patients appropriately to manage symptoms and improve their quality of life during treatment.</li><li>\u27a4 patients receiving chemotherapy</li><li>\u27a4 Oxaliplatin</li><li>\u27a4 unusual sensations in the throat and laryngeal area</li><li>\u27a4 response to cold,</li><li>\u27a4 due to pharyngolaryngeal dysesthesia</li><li>\u27a4 clinicians to be aware of this potential side</li><li>\u27a4 effect</li><li>\u27a4 counsel patients</li><li>\u27a4 manage symptoms</li><li>\u27a4 improve their quality of life during treatment.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "71b74bb5",
      "audio": ""
    },
    {
      "text": "Which of the following is a US-FDA approved anti-CD 20 monoclonal antibody for primary progressive multiple sclerosis?",
      "options": [
        {
          "label": "A",
          "text": "Alemtuzumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ocrelizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Natalizumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pertuzumab",
          "correct": false
        }
      ],
      "correct_answer": "B. Ocrelizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Ocrelizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Alemtuzumab: Alemtuzumab targets CD52 , a protein expressed on the surface of T and B lymphocytes , and is used in the treatment of relapsing-remitting multiple sclerosis, but not for PPMS.</li><li>\u2022 Option A. Alemtuzumab:</li><li>\u2022 targets CD52</li><li>\u2022 protein</li><li>\u2022 surface of T and B lymphocytes</li><li>\u2022 used in</li><li>\u2022 relapsing-remitting multiple sclerosis,</li><li>\u2022 Option C. Natalizumab: Natalizumab targets integrin alpha-4 , involved in the migration of leukocytes across the blood-brain barrier. It is used for relapsing forms of multiple sclerosis and not indicated for PPMS.</li><li>\u2022 Option C. Natalizumab:</li><li>\u2022 targets integrin alpha-4</li><li>\u2022 migration of leukocytes across the blood-brain barrier.</li><li>\u2022 used</li><li>\u2022 relapsing forms of multiple sclerosis</li><li>\u2022 Option D. Pertuzumab: Pertuzumab is a monoclonal antibody that targets the HER2 receptor, which is overexpressed in HER2-positive breast cancer. It is not used in the treatment of multiple sclerosis.</li><li>\u2022 Option D. Pertuzumab:</li><li>\u2022 monoclonal antibody</li><li>\u2022 targets the HER2 receptor,</li><li>\u2022 overexpressed in HER2-positive breast cancer.</li><li>\u2022 not</li><li>\u2022 treatment of multiple sclerosis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ocrelizumab is the first and only US-FDA approved therapy specifically indicated for primary progressive multiple sclerosis.</li><li>\u27a4 Ocrelizumab</li><li>\u27a4 first and only US-FDA</li><li>\u27a4 primary progressive multiple sclerosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "787011bf",
      "audio": ""
    },
    {
      "text": "The dose of which of the following drugs should be reduced when prescribed along with allopurinol?",
      "options": [
        {
          "label": "A",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "B",
          "text": "6 Mercaptopurine",
          "correct": true
        },
        {
          "label": "C",
          "text": "6 Thioguanine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Capacitabine",
          "correct": false
        }
      ],
      "correct_answer": "B. 6 Mercaptopurine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 6 mercaptopurine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Methotrexate: While methotrexate is metabolized by the liver and excreted by the kidneys, a llopurinol does not significantly affect its plasma levels. However, close monitoring is still warranted due to the potential for increased toxicity, but specific dose reduction due to allopurinol is not a standard practice.</li><li>\u2022 Option A. Methotrexate:</li><li>\u2022 metabolized by the liver</li><li>\u2022 excreted by the kidneys,</li><li>\u2022 llopurinol</li><li>\u2022 does not</li><li>\u2022 its plasma levels.</li><li>\u2022 close monitoring</li><li>\u2022 potential for increased toxicity,</li><li>\u2022 specific dose reduction</li><li>\u2022 allopurinol</li><li>\u2022 not a standard practice.</li><li>\u2022 Option C. 6-Thioguanine: Like 6-MP, 6-thioguanine is a purine analog , and though it has a similar mechanism of action , the effect of allopurinol on its metabolism does not usually require a dose adjustment.</li><li>\u2022 Option C. 6-Thioguanine:</li><li>\u2022 6-MP, 6-thioguanine is a purine analog</li><li>\u2022 similar mechanism of action</li><li>\u2022 allopurinol</li><li>\u2022 its metabolism</li><li>\u2022 does not</li><li>\u2022 dose adjustment.</li><li>\u2022 Option D. Capecitabine: Capecitabine, an oral prodrug that is metabolized into 5-fluorouracil, is not primarily affected by allopurinol, and dose adjustments are typically not necessary when these drug s are used concurrently.</li><li>\u2022 Option D. Capecitabine:</li><li>\u2022 oral prodrug</li><li>\u2022 metabolized into 5-fluorouracil,</li><li>\u2022 not</li><li>\u2022 affected</li><li>\u2022 allopurinol,</li><li>\u2022 dose adjustments</li><li>\u2022 not</li><li>\u2022 drug</li><li>\u2022 used concurrently.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When prescribing 6-Mercaptopurine in conjunction with allopurinol, it's essential to reduce the dosage of 6-MP to prevent increased drug levels and potential toxicity due to the inhibition of xanthine oxidase by allopurinol.</li><li>\u27a4 prescribing 6-Mercaptopurine</li><li>\u27a4 conjunction with allopurinol,</li><li>\u27a4 reduce the dosage of 6-MP to prevent</li><li>\u27a4 increased drug levels</li><li>\u27a4 potential toxicity</li><li>\u27a4 inhibition of xanthine oxidase by allopurinol.</li><li>\u27a4 This drug interaction underscores the importance of understanding the metabolic pathways of chemotherapeutic agents and the impact of concomitant medications on these pathways.</li><li>\u27a4 drug interaction</li><li>\u27a4 underscores</li><li>\u27a4 metabolic pathways of chemotherapeutic agents</li><li>\u27a4 impact of concomitant medications</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "af2ceddb",
      "audio": ""
    },
    {
      "text": "A 45-year-old male patient is being treated with ABVD chemotherapy for Hodgkin lymphoma. He presents for cycle 4 of a planned 6 cycles with a new-onset cough. He states it started a week ago and he also feels like he has a little trouble catching his breath. Which drug in the ABVD regimen is the most likely cause of his pulmonary toxicity?",
      "options": [
        {
          "label": "A",
          "text": "Doxorubicin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bleomycin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vinblastine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dacarbazine",
          "correct": false
        }
      ],
      "correct_answer": "B. Bleomycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Bleomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Doxorubicin : As part of the ABVD regimen, doxorubicin's primary toxicities are cardiotoxicity and myelosuppression . Pulmonary toxicity is not a common side effect of doxorubicin.</li><li>\u2022 Option A.</li><li>\u2022 Doxorubicin</li><li>\u2022 As part</li><li>\u2022 ABVD regimen,</li><li>\u2022 doxorubicin's</li><li>\u2022 cardiotoxicity and myelosuppression</li><li>\u2022 Pulmonary toxicity</li><li>\u2022 not</li><li>\u2022 doxorubicin.</li><li>\u2022 Option C. Vinblastine : Another component of the ABVD regimen , vinblastine typically causes side effects such as neurotoxicity and myelosuppression. It is not generally associated with pulmonary toxicity.</li><li>\u2022 Option C.</li><li>\u2022 Vinblastine</li><li>\u2022 Another component</li><li>\u2022 ABVD regimen</li><li>\u2022 neurotoxicity and</li><li>\u2022 myelosuppression.</li><li>\u2022 not</li><li>\u2022 pulmonary toxicity.</li><li>\u2022 Option D. Dacarbazine : The final drug in the ABVD regimen , dacarbazine can cause nausea, vomiting, and myelosuppression, but like the others, it is not known for causing pulmonary toxicity.</li><li>\u2022 Option D.</li><li>\u2022 Dacarbazine</li><li>\u2022 final drug</li><li>\u2022 ABVD regimen</li><li>\u2022 dacarbazine</li><li>\u2022 nausea, vomiting, and myelosuppression,</li><li>\u2022 not</li><li>\u2022 causing pulmonary toxicity.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients undergoing ABVD chemotherapy who develop respiratory symptoms such as coughing and shortness of breath, Bleomycin is the agent within the regimen most likely to be responsible for pulmonary toxicity.</li><li>\u27a4 patients</li><li>\u27a4 undergoing ABVD chemotherapy</li><li>\u27a4 respiratory symptoms</li><li>\u27a4 coughing and shortness of breath,</li><li>\u27a4 Bleomycin</li><li>\u27a4 agent</li><li>\u27a4 most likely</li><li>\u27a4 responsible for pulmonary toxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "912c7182",
      "audio": ""
    },
    {
      "text": "A 64-year-old male about to undergo therapy for Rhabdomyosarcoma. His chemotherapy includes vincristine, dactinomycin, cyclophosphamide, doxorubicin and ifosfamide. Which of the following is most appropriate to include in chemotherapy orders for this patient?",
      "options": [
        {
          "label": "A",
          "text": "IV hydration, mesna, and frequent urinalyses",
          "correct": true
        },
        {
          "label": "B",
          "text": "Leucovorin and frequent urinalyses",
          "correct": false
        },
        {
          "label": "C",
          "text": "Allopurinol and frequent urinalyses",
          "correct": false
        },
        {
          "label": "D",
          "text": "IV hydration, prophylactic antibiotics, and frequent urinalyses",
          "correct": false
        }
      ],
      "correct_answer": "A. IV hydration, mesna, and frequent urinalyses",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) IV hydration, mesna, and frequent urinalyses.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Leucovorin and frequent urinalyses. Leucovorin is used in combination with the methotrexate, which is not included in the listed chemotherapy drugs.</li><li>\u2022 Option B. Leucovorin and frequent urinalyses.</li><li>\u2022 Leucovorin</li><li>\u2022 combination with the methotrexate,</li><li>\u2022 not</li><li>\u2022 listed chemotherapy drugs.</li><li>\u2022 Option C. Allopurinol and frequent urinalyses . Allopurinol is used to prevent uric acid buildup during chemotherapy for lymphoma but is not used for rhabdomyosarcoma.</li><li>\u2022 Option C. Allopurinol and frequent urinalyses</li><li>\u2022 Allopurinol</li><li>\u2022 prevent uric acid buildup</li><li>\u2022 chemotherapy for lymphoma</li><li>\u2022 not</li><li>\u2022 rhabdomyosarcoma.</li><li>\u2022 Option D. IV hydration, prophylactic antibiotics, and frequent urinalyses . Prophylactic antibiotics may be used to prevent infections during chemotherapy , but is not typically required for rhabdomyosarcoma chemotherapy.</li><li>\u2022 Option D. IV hydration, prophylactic antibiotics, and frequent urinalyses</li><li>\u2022 Prophylactic antibiotics</li><li>\u2022 prevent infections</li><li>\u2022 during chemotherapy</li><li>\u2022 not</li><li>\u2022 required for rhabdomyosarcoma chemotherapy.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For patients receiving chemotherapy regimens that include cyclophosphamide and ifosfamide, it is crucial to implement measures to prevent bladder toxicity. This includes the use of IV hydration to facilitate dilution of urine, mesna to chemically neutralize toxic metabolites, and regular monitoring of urinary function through frequent urinalyses . These steps are essential to protect the patient\u2019s urinary tract and ensure the safe administration of potentially nephrotoxic chemotherapy agents.</li><li>\u27a4 patients receiving chemotherapy regimens</li><li>\u27a4 cyclophosphamide and ifosfamide,</li><li>\u27a4 implement measures</li><li>\u27a4 prevent bladder toxicity.</li><li>\u27a4 use of IV hydration to facilitate dilution of urine, mesna to chemically neutralize toxic</li><li>\u27a4 metabolites,</li><li>\u27a4 regular monitoring of urinary function</li><li>\u27a4 frequent urinalyses</li><li>\u27a4 steps</li><li>\u27a4 essential to protect</li><li>\u27a4 patient\u2019s urinary tract</li><li>\u27a4 safe administration of potentially nephrotoxic chemotherapy agents.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cbbffeed",
      "audio": ""
    },
    {
      "text": "Vinblastine inhibits which phase of cell cycle?",
      "options": [
        {
          "label": "A",
          "text": "G1 phase",
          "correct": false
        },
        {
          "label": "B",
          "text": "S phase",
          "correct": false
        },
        {
          "label": "C",
          "text": "G2 phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "M phase",
          "correct": true
        }
      ],
      "correct_answer": "D. M phase",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-153051.png"
      ],
      "explanation": "<p><strong>Ans. D) M phase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. G1 phase: This phase involves the preparation of the cell to enter the S phase but is not affected by vinblastine.</li><li>\u2022 Option A. G1 phase:</li><li>\u2022 preparation of the cell to enter the S phase</li><li>\u2022 not</li><li>\u2022 vinblastine.</li><li>\u2022 Option B. S phase: The phase where DNA replication occurs ; vinblastine does not directly affect DNA synthesis.</li><li>\u2022 Option B. S phase:</li><li>\u2022 DNA replication occurs</li><li>\u2022 vinblastine does not</li><li>\u2022 DNA synthesis.</li><li>\u2022 Option C. G2 phase: The phase where the cell prepares for mitosis ; although important for cell cycle progression, vinblastine specifically targets and disrupts the mitotic phase rather than this preparatory phase.</li><li>\u2022 Option C. G2 phase:</li><li>\u2022 cell prepares for mitosis</li><li>\u2022 cell cycle progression,</li><li>\u2022 vinblastine</li><li>\u2022 targets and disrupts</li><li>\u2022 mitotic phase rather</li><li>\u2022 this preparatory phase.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3bef4bbf",
      "audio": ""
    },
    {
      "text": "After 15 days of chemotherapy, a patient develops rash and itching on the back as shown in the image. It can occur as a side effect of which of the following drugs?",
      "options": [
        {
          "label": "A",
          "text": "Actinomycin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Doxorubicin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bleomycin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Mitomycin C",
          "correct": false
        }
      ],
      "correct_answer": "C. Bleomycin",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/415.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Bleomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Actinomycin: While actinomycin can cause side effects including nausea and myelosuppression, it is not typically associated with flagellate pigmentation.</li><li>\u2022 Option A. Actinomycin:</li><li>\u2022 side effects</li><li>\u2022 nausea and myelosuppression,</li><li>\u2022 not</li><li>\u2022 flagellate pigmentation.</li><li>\u2022 Option B. Doxorubicin: Doxorubicin's side effect profile includes cardiotoxicity and myelosuppression ; flagellate pigmentation is not a common reaction with this drug.</li><li>\u2022 Option B. Doxorubicin:</li><li>\u2022 side effect</li><li>\u2022 cardiotoxicity and myelosuppression</li><li>\u2022 flagellate pigmentation</li><li>\u2022 not</li><li>\u2022 this drug.</li><li>\u2022 Option D. Mitomycin C: This chemotherapeutic agent is more commonly associated with bone marrow suppression and renal toxicity, not the distinctive skin pigmentation seen with Bleomycin.</li><li>\u2022 Option D. Mitomycin C:</li><li>\u2022 chemotherapeutic agent</li><li>\u2022 bone marrow suppression and renal</li><li>\u2022 toxicity, not</li><li>\u2022 skin pigmentation</li><li>\u2022 Bleomycin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Flagellate pigmentation is a distinctive cutaneous side effect associated with Bleomycin therapy.</li><li>\u27a4 Flagellate pigmentation</li><li>\u27a4 distinctive cutaneous side effect</li><li>\u27a4 Bleomycin therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "50232dda",
      "audio": ""
    },
    {
      "text": "Which of the following is an inhibitor of DNA replication?",
      "options": [
        {
          "label": "A",
          "text": "Actinomycin D",
          "correct": false
        },
        {
          "label": "B",
          "text": "Asparaginase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mitomycin",
          "correct": false
        },
        {
          "label": "D",
          "text": "6-mercaptopurine",
          "correct": true
        }
      ],
      "correct_answer": "D. 6-mercaptopurine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) 6-mercaptopurine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Actinomycin D: This drug binds to DNA and inhibits RNA polymerase, which is responsible for transcribing RNA from the DNA template. While it does affect genetic material, it is not a direct inhibitor of DNA replication.</li><li>\u2022 Option A. Actinomycin D:</li><li>\u2022 binds</li><li>\u2022 DNA and inhibits RNA polymerase,</li><li>\u2022 transcribing RNA from the</li><li>\u2022 DNA template.</li><li>\u2022 affect genetic material,</li><li>\u2022 not</li><li>\u2022 direct inhibitor of DNA replication.</li><li>\u2022 Option B. Asparaginase: Works by breaking down the amino acid asparagine , which is necessary for protein synthesis in tumor cells. It does no t directly inhibit DNA replication.</li><li>\u2022 Option B. Asparaginase:</li><li>\u2022 Works</li><li>\u2022 breaking down</li><li>\u2022 amino acid asparagine</li><li>\u2022 protein synthesis in tumor cells.</li><li>\u2022 does no</li><li>\u2022 inhibit DNA replication.</li><li>\u2022 Option C. Mitomycin: Acts as an alkylating agent , forming cross-links within the DNA strands . Although this affects DNA structure and function , it does not inhibit the replication process directly like 6-MP does.</li><li>\u2022 Option C. Mitomycin:</li><li>\u2022 alkylating agent</li><li>\u2022 cross-links</li><li>\u2022 DNA strands</li><li>\u2022 affects DNA structure</li><li>\u2022 function</li><li>\u2022 does not</li><li>\u2022 inhibit</li><li>\u2022 replication process directly like 6-MP does.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 6-mercaptopurine is a crucial medication in the treatment of certain types of leukemia, where it serves as an inhibitor of DNA replication by mimicking purine nucleotides. This specific action disrupts the synthesis of DNA , which is critical for the proliferation of cancer cells.</li><li>\u27a4 6-mercaptopurine</li><li>\u27a4 crucial medication</li><li>\u27a4 leukemia,</li><li>\u27a4 serves as an inhibitor of DNA</li><li>\u27a4 replication</li><li>\u27a4 mimicking purine nucleotides.</li><li>\u27a4 disrupts the synthesis of DNA</li><li>\u27a4 critical for the proliferation</li><li>\u27a4 cancer cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8ad971da",
      "audio": ""
    },
    {
      "text": "Neurotoxicity is dose-limiting for which of the following drugs?",
      "options": [
        {
          "label": "A",
          "text": "Etoposide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paclitaxel",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vincristine",
          "correct": true
        }
      ],
      "correct_answer": "D. Vincristine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Vincristine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Etoposide: Etoposide can cause myelosuppression , leading to low blood cell counts, which is generally the dose-limiting toxicity for this drug.</li><li>\u2022 Option A. Etoposide:</li><li>\u2022 myelosuppression</li><li>\u2022 low blood cell counts,</li><li>\u2022 dose-limiting</li><li>\u2022 toxicity</li><li>\u2022 Option B. Methotrexate: While methotrexate can cause various side effects including mucositis and hepatotoxicity, its dose-limiting toxicity is often myelosuppression.</li><li>\u2022 Option B. Methotrexate:</li><li>\u2022 side effects</li><li>\u2022 mucositis and hepatotoxicity,</li><li>\u2022 dose-limiting</li><li>\u2022 toxicity</li><li>\u2022 myelosuppression.</li><li>\u2022 Option C. Paclitaxel: Paclitaxel can cause myelosuppression and neuropathy , but the primary dose-limiting toxicity is typically bone marrow suppression.</li><li>\u2022 Option C. Paclitaxel:</li><li>\u2022 myelosuppression and neuropathy</li><li>\u2022 primary dose-limiting toxicity</li><li>\u2022 bone</li><li>\u2022 marrow suppression.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vincristine's dose-limiting toxicity is neurotoxicity, which necessitates careful monitoring of neurological symptoms and adjustment of dosing to prevent severe peripheral neuropathy.</li><li>\u27a4 Vincristine's dose-limiting toxicity</li><li>\u27a4 neurotoxicity,</li><li>\u27a4 monitoring of neurological symptoms</li><li>\u27a4 adjustment</li><li>\u27a4 dosing</li><li>\u27a4 prevent severe peripheral neuropathy.</li><li>\u27a4 Myelosuppression is dose limiting for paclitaxel, etoposide, and methotrexate.</li><li>\u27a4 Myelosuppression</li><li>\u27a4 dose limiting</li><li>\u27a4 paclitaxel, etoposide, and methotrexate.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c9e9bd4e",
      "audio": ""
    },
    {
      "text": "Nivolumab is used in the treatment of?",
      "options": [
        {
          "label": "A",
          "text": "Hodgkin\u2019s lymphoma",
          "correct": true
        },
        {
          "label": "B",
          "text": "Medulloblastoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Retinoblastoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Endometrial carcinoma",
          "correct": false
        }
      ],
      "correct_answer": "A. Hodgkin\u2019s lymphoma",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/02/416.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Hodgkin\u2019s lymphoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Medulloblastoma: Not a primary indication for nivolumab.</li><li>\u2022 Option B. Medulloblastoma:</li><li>\u2022 Not</li><li>\u2022 nivolumab.</li><li>\u2022 Option C. Retinoblastoma: Not treated with nivolumab.</li><li>\u2022 Option C. Retinoblastoma:</li><li>\u2022 Not</li><li>\u2022 nivolumab.</li><li>\u2022 Option D. Endometrial carcinoma: Pembrolizumab is more commonly associated with endometrial carcinoma, not nivolumab.</li><li>\u2022 Option D. Endometrial carcinoma:</li><li>\u2022 Pembrolizumab</li><li>\u2022 endometrial carcinoma, not nivolumab.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Important indications of Immune Check Point Inhibitors</li><li>\u27a4 indications</li><li>\u27a4 Immune Check Point Inhibitors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "20923423",
      "audio": ""
    },
    {
      "text": "A 20-year-old boy presented with slow growing mass on the medial side of thigh. Investigations revealed it to be osteosarcoma and patient was started on methotrexate. Mechanism of action of methotrexate as an anticancer drug is:",
      "options": [
        {
          "label": "A",
          "text": "Inhibition of Dihydrofolate reductase",
          "correct": true
        },
        {
          "label": "B",
          "text": "Inhibition of N5 tetrahydro folate reductase",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibition of tyrosine kinase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibition of purine metabolism",
          "correct": false
        }
      ],
      "correct_answer": "A. Inhibition of Dihydrofolate reductase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Inhibition of Dihydrofolate reductase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Inhibition of N5 tetrahydro folate reductase: This option is incorrect because there is no enzyme named N5 tetrahydro folate reductase that methotrexate is known to inhibit.</li><li>\u2022 Option B. Inhibition of N5 tetrahydro folate reductase:</li><li>\u2022 incorrect</li><li>\u2022 no enzyme</li><li>\u2022 N5 tetrahydro</li><li>\u2022 folate reductase</li><li>\u2022 methotrexate</li><li>\u2022 inhibit.</li><li>\u2022 Option C. Inhibition of tyrosine kinase: This is the action of drugs like imatinib, not methotrexate. Tyrosine kinase inhibitors are used in the treatment of certain types of leukemia.</li><li>\u2022 Option C. Inhibition of tyrosine kinase:</li><li>\u2022 action of</li><li>\u2022 imatinib,</li><li>\u2022 not methotrexate. Tyrosine kinase inhibitors</li><li>\u2022 used</li><li>\u2022 types of leukemia.</li><li>\u2022 Option D. Inhibition of purine metabolism: While methotrexate can impact purine metabolism indirectly by its action on DHFR , the direct inhibition of purine metabolism is characteristic of drugs like 6-mercaptopurine, not methotrexate.</li><li>\u2022 Option D. Inhibition of purine metabolism:</li><li>\u2022 methotrexate</li><li>\u2022 impact purine metabolism indirectly</li><li>\u2022 its action</li><li>\u2022 DHFR</li><li>\u2022 direct inhibition of purine metabolism</li><li>\u2022 6-mercaptopurine, not methotrexate.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The key mechanism of action of methotrexate in the treatment of cancer , including osteosarcoma, is the inhibition of dihydrofolate reductase. This action results in decreased nucleotide biosynthesis , which is vital for DNA replication and cell division in rapidly dividing cancer cells.</li><li>\u27a4 mechanism of action</li><li>\u27a4 methotrexate</li><li>\u27a4 cancer</li><li>\u27a4 osteosarcoma,</li><li>\u27a4 inhibition of dihydrofolate</li><li>\u27a4 reductase.</li><li>\u27a4 decreased nucleotide biosynthesis</li><li>\u27a4 vital for DNA replication</li><li>\u27a4 cell division in rapidly</li><li>\u27a4 dividing cancer cells.</li><li>\u27a4 Understanding this mechanism is critical when using methotrexate as an anticancer agent , as it informs both its therapeutic effects and its toxicity profile.</li><li>\u27a4 mechanism</li><li>\u27a4 using methotrexate</li><li>\u27a4 anticancer agent</li><li>\u27a4 both its therapeutic effects</li><li>\u27a4 and its toxicity profile.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f2d6e202",
      "audio": ""
    }
  ]
}